Turnaround time (TAT) is a retrospective quality indicator for laboratory tests. The real-time display of the ongoing phases of laboratory tests would be helpful for clinicians to estimate the duration required to obtain result reports. Additionally, the expert comments by laboratory physicians about the test results through the Order Communication System (OCS) would contribute to the increase in laboratory test utilization.
Background-aim
Turnaround time (TAT) is a retrospective quality indicator for laboratory tests. The real-time display of the ongoing phases of laboratory tests would be helpful for clinicians to estimate the duration required to obtain result reports. Additionally, the expert comments by laboratory physicians about the test results through the Order Communication System (OCS) would contribute to the increase in laboratory test utilization.
Methods
We upgraded our OCS program to enable the real-time display of the ongoing phases of laboratory tests process, which are categorized as follows: 1) test request, 2) label printing, 3) sampling, 4) receipt by laboratory, 5) test carry out (manual or automated), 6) result verification, 7) interpretation by laboratory physician and 8) result final report. Additionally, the feature enabling the easy adding and browsing of expert comments with regard to test results in OCS was installed.
Results
This upgraded OCS system has enabled clinicians to know what phases the requested laboratory tests are in at present in real-time. Additionally, this system has allowed laboratory physicians to put interpretative expert comments about test results, even for not specialized routine tests (e.g., HbA1c, CBC) that does not normally add interpretive comments.
Conclusions
We have successfully developed the OCS function for the realtime display of test phases and expert comments by laboratory physicians. This function would contribute to the satisfaction of the clinician for the laboratory services and ultimately increase laboratory test utilization. 
Background-aim
In inflammatory and infectious diseases, the cellular components in serous fluids are increased rendering essential diagnostic information. Sample testing should occur within one-hour post collection to avoid cellular deterioration or lysis. The aim of this study was to evaluate the usefulness of BD Vacutainer® Urianalysis tube (BDUt) for serous fluids cell counts.
Methods
Retrospective data of 21560 urinalysis performed over 1 year from November 2016 to October 2016 were retrieved from the Laboratory Information System. The urine collection time, laboratory receiving time, whether the urine specimens were refrigerated before reaching the laboratory and ordering locations were evaluated.
Results
We found that 91.5% of the specimens were received in the laboratory within 2 hours of collection and not refrigerated previously. Another 3.8% of the specimens were delivered from a nearby healthcare facility. Although the specimens were received beyond 2 hours of collection time, they were refrigerated prior to transportation and therefore met the preanalytical quality requirements. The remaining 4.7% of the specimens were received beyond the 2 hours of collection time and were never refrigerated. Of the 1006 urine specimens that exceeded the quality requirements for handling, 82% and 18% were from inpatients and outpatients, respectively.
Conclusions
When compared to the CAP Q-Probes 1997 study, our audit showed excellent compliance to recommended standards and quality guidelines. We will continue to monitor and emphasize to our clinical colleagues the importance of preanalytical handling of urinalysis specimens. 
Background-aim
Procalcitonin (PCT) is produced mainly in the parafollicular cells of the thyroid and it is one of the most reliable diagnostic markers for bacterial infection; its level are related to the severity and mortality of the infectious disease. PCT results greater than 0.5 mg/L are related to the occurrence of sepsis. The implementation of the PCT test supposes a high cost because each determination costs 8.71
€.
The objective was to analyze the requests with joint demand of CRP and PCT, and to implement a protocol with adequacy of the PCT demand for a better use of the resources of the Emergency Laboratory.
Methods
Descriptive and retrospective study of all PCT requests received in the Biochemistry Emergency Laboratory during 2017; a total of 5016 samples were analyzed. CRP and PCT measurements were performed on a Roche Diagnostics COBAS 8000 analyzer by turbidimetry and immunoassay, respectively. For the statistical analysis, the MedCalc program were used. The ROC curve were used to analyze the diagnostic efficiency, as well as the cut-off point.
Results
The ROC curve analysis shows, for a cut-off value of 20 mg/L of CRP, a sensitivity of 96.80%. The diagnosis of sepsis was confirmed in 29.43% of cases due to elevated CRP and PCT results, and was ruled out in 21.05% of cases because both determinations were in the normal range. Only in the 0.48% of the cases studied the CRP results were normal while the PCT results were pathological.
Conclusions
Based on the published scientific evidence, we conclude that it is necessary to implement a protocol to adapt the demand to avoid unnecessary tests and to make rational use of the laboratory resources. Because of this, the PCT test should not be performed if there is no CRP value higher than 20 mg/L, except in cases where there is clinical suspicion of sepsis. It would also be necessary to perform the PCT determination, without regard the CRP results, in neonates and in the ICU samples.
During the time studied, 1080 requests of PCT (21.53%) should have been canceled. After the implementation of this protocol, the savings would have been 9406.8€. In addition, the response time of the emergency laboratory would be reduced because the PCT determination takes longer to be made, delaying the delivery of the results. 
Background-aim
Laboratory turnaround time (TAT) is one of the most important indicators of the quality and effectiveness of laboratory performance. In this study, we aimed to evaluate the effects of new barcode type usage for emergency department (ED) on TAT analysis of Troponin T test T in the emergency department (ED) of university hospital.
Methods
This study was carried out in the Clinical Biochemistry Laboratory of Pamukkale University in January-December 2018, for Troponin T test. In July, we started to use new barcode type which has red mark on the upper side. TAT was calculated in January-June and JulyDecember 2018. TAT was calculated from the time when blood samples arrived at the laboratory and the time of completion and reporting of the test.The agreed TAT for Troponin T in our laboratory is 120 minutes.
Results
Between January-June 2018, total number of analyzed Troponin T were 14413 and the TAT averages were 114 minutes. During JulyDecember 2018, after new barcode the number of analyzed test was 14087 and the TAT averages were 92 minutes.
Conclusions
Everyday hundreds to thousands of samples (both routine and emergency) analyse in the Central Biochemistry Laboratory. During this laboratory workload technicians may be delayed to detect and analyze emergency samples. TAT time was shortened by increasing the awareness of technicians with new barcode application. 
Background-aim
Hemolysis is preanalytical incidence with a prevalence around 3,3%. It is the most frecuent cause of rejected samples in the laboratory. However, hemolysis effect in basic coagulation parameters (prothrombin time (PT) and activated partial thromboplastin time (APTT)) has been less studied. The aim of our study is evaluate the influence of hemolysis in these analytes.
Methods
We made two pools of plasma: one with patients which INR was less than 1,5 and another group with INR more tan 1.5. In both pools were performed hemolysis in vitro adding growing concentration of Hemoglobin (Hb) from 25 to 2000 mg/dl (25, 50, 100, 200, 400, 500, 1000, 2000) . All samples generated were processed in CA-500 (Sysmex®) to obtain basic coagulation tests (PT and APTT). Differences pre and post hemolysis were evaluated according to Spanish Minimum Consensus Performance Specifications (SMCPS).
Results
Both in the INR group b 1.5 and in groupN 1.5, percentage of change (PC), for TP and APTT, in the different grades of hemolysis, was lower than that published by SMPC (31% and 24% respectively). For the TP the maximum change was 6% with a concentration of Hb of 1 mg/dl whereas for the APTT was 9% with 0.5 mg/dl Hb. No linear relationship was observed between increased hemolysis and PC.
Conclusions
Our results have shown that TP and APTT, do not undergo clinically significant changes after hemolysis and question the policy of rejection of samples published by CLSI guidelines.
Our future goal is investigate effect of hemolysis in patients with anticoagulant treatment. The aim of the study was to comprise of methods for serum determination of 25OHD (automatic CLIA on IDS-iSYS and LIAISON analyzers) and 1,25(OH) 2 D (semi-automatic CLIA on IDS-iSYS analyzer and manual RIA) in pediatric and DEQAS samples.
Methods
The intra-and inter-variability (CV intra and CV inter ) of 25OHD and 1,25(OH) 2 D measurements on the IDS-iSYS platform in pediatric samples were calculated. The comparison of the IDS-iSYS CLIA methods of 25OHD and 1,25(OH) 2 D determinations with the LIAISON CLIA and manual RIA methods, respectively, was performed. The accuracy of the CLIA method of 25OHD quantification on the IDS-iSYS was evaluated using DEQAS HPLC and LC-MS/MS data.
Results
The CLIA methods of 25OHD and 1,25(OH) 2 D determinations on the IDS-iSYS platform were characterized by high repeatability (CV intra 2.6% and 6.4%, respectively) and reproducibility (CV inter 9.1% and 9.6%, respectively). Measurement of 25OHD concentration in pediatric and DEQAS samples showed, respectively, 25.7% and 49.4% bias between methods. The comparison of methods of 1,25 (OH) 2 D determination showed their good compatibility in pediatric samples (bias of 11.0%).
Conclusions
The study indicate high precision of serum 25OHD and 1, 25(OH) 2 D determinations using CLIA methods on the IDS-iSYS platform. This made the possibility of their use in clinical practice of pediatric hospital with maintenance of the highest diagnostic standards. The disagreement noted between methods of 25OHD determination may be due to differences in the cross-reactivity with the vitamin D metabolites. 
Background-aim
One of the main objectives of a clinical laboratory is getting precise and accurate values. For instance, to quantify the hemolysis, the study of serum index such as hemolytic one is a widespread practice. Hemolysis can take place both in vivo and in vitro. The latter is being the most frequent one. Breaking the red cell can produce interferences through several mechanisms, altering the absorption spectrum, by chemical interferences, by release intracellular components and by dilution of the components of the sample.
Due to a change of analyzers, the present hemolysis interference study is aiming to quantify the possible change in 73 tests performed by different techniques in such equipment: spectrophotometry, indirect potentiometric and immunological techniques.
Methods
The tests were performed in a Roche Diagnostics Cobas 8000 equipment following the protocol of the Spanish Society of Laboratory Medicine (SEQCml): "Procedure for the study of interference by haemolysis, bilirubin and turbidity and for the verification of the rates of hemolysis, jaundice and lipemia".
Results
The results were compared with those reported in the inserts provided by Roche Diagnostics of the different techniques. The tests were performed in a Roche Diagnostics Cobas 8000 equipment following the protocol of the Spanish Society of Laboratory Medicine (SEQCml): "Procedure for the study of interference by haemolysis, bilirubin and turbidity and for the verification of the rates of hemolysis, jaundice and lipemia".
To assess the existence of interferences, the limit used by the manufacturer (10%) was taken as the maximum admissible error criterion. The interference was obtained for the following compounds: amylase, aspartate aminotransferase (AST), direct bilirubin (DBil), creatinine kinase (CK), alkaline phosphatase (ALP), iron, lactate dehydrogenase (LDH), lipase, magnesium, phosphorus, potassium, triglycerides, thyroid antiperoxidase antibodies (ATPO), Anti-receptor antibodies of TSH (ATSHR), folate, ultrasensitive troponin T (hs-cTnT), insulin, parathyroid hormone (PTH) and progesterone.
Conclusions
Working with new analyzers, it is important to study the dependence of the results of the interference of the hemolysis on the used differentanalytical techniques, as it has an impact on the medical decision making.
In clinical practice, it is recommended to determine the hemolytic index, to detect and quantify the interference by hemolysis, assessing the possible rejection of samples and providing reliable reports helping clinicians to interpret the results. 
Background-aim
Mycophenolic acid (MPA) is an immunosuppressant that inhibits the de novo pathway of guanosine nucleotide synthesis acting as a reversible and uncompetitive inhibitor of inosine monophosphate dehydrogenase, reducing the intracellular reserves of guanosine nucleotides and blocking the lymphocyte proliferation It is administered as mycophenolate, a prodrug that is metabolized at the liver to the active substance, MPA. Renal, hepatic or cardiac transplant patients usually receive MPA along with another immunosuppressant, however it is also used as monotherapy for the treatment of autoimmune diseases. the low frequency of adverse effects makes the MPA very useful, especially in the pediatric population.
The aim of our study is to evaluate the interchangeability of MAP levels, measured by enzyme immunoassay technique in two different analyzers: AU-680 (Beckman Coulter®) and Cobas C 501 (Roche®).
Methods
82 serum samples, mainly from pediatric nephrology service patients, were recollected. serum MPA levels were measured in both analyzers. First, from every serum sample an aliquot was frozen and another sent to an external laboratory and analyzed in the same week of its recollection in the Cobas C 501 (Roche®). Then all the frozen aliquots were thawed and analyzed all together in our AU-680 (Beckman Coulter®) analyzer. Bothe analyzers had a working range of 0.3-10 ug/mL.
Following the 2011 recommendations of The Spanish Society of Laboratory Medicine (SEQC) for methods comparison studies, Passing Bablok regression and Bland Altman plot were obtained using MedCalc statistical software.
Results
We obtained the following results: Bland Altman plot with mean= 0 ± 0.81 ug/mL and Passing Bablok regression equation Y = -0.32 ± 1.17X where Y= AU-680 and X= Cobas C 501
Conclusions
Although according to the statistical results, there is a proportional and constant differences between the two analyzers, we consider them clinically insignificants, and we can conclude that both analyzers are interchangeable.
Thanks to those results, our laboratory can carry out the measurement of all the immunosuppressants used in renal transplanted patients, becoming the reference kidney transplantation hospital in our province. doi:10.1016/j.cca.2019.03.1506
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Background-aim N-terminal natriuretic peptide (NT-proBNP) assay is useful in diagnosis, prognosis and monitoring patients with heart failure.
Our goal was to verify the specifications of systematic error (SE) provided by the manufacturer, for a new procedure used in serum NT-proBNP test values.
Methods
The analizer used have been the IMMULITE® 2000 (Siemens Healthineers), for comparison procedure; and the ADVIA Centaur XP® (Siemens), for evaluated procedure.
The NT-proBNP test was done by chemiluminescent immunometric assay.
For the study of veracity 50 samples of patients were processed along various series, following the protocol by the Sociedad Española de Medicina de Laboratorio (SEQCML).
Results
Study of veracity was made using 2 methods: Differences analysis: we obtained an average value the relative differences of -34 pg/mL (CI95%: -98, -287). The 95% confidence interval (CI95%) of the average of the absolute and relative differences did not include the zero value.
Lineal regression analysis: we obtained a correlation coefficient (r) of 0.992, making the selected value intervals, being greater than 0.975. The obtained slope was 0.968 (CI95%: 0.944, 0.993) and the ordinate in the origin -134 (CI95%: -33, -234). The CI95% of the values in the ordinate in the origin did not contain the zero value. The CI95% of the values of the slope did not contain the value 1.
We observed a mixed SE in the evaluated procedure (constant and proportional). We estimated the SE starting from the slope value (b) being 3.17%.
Conclusions
According to the differences analysis there is a constant and proportional SE. On the other hand the CI95% of the values of the slope and ordinate in the origin indicate that the evaluated procedure provides significantly different values to the comparison procedure, having also constant and proportional systematic differences.
The SE calculated is lower than that recommended in the specifications according to the SEQCML for NT-proBNP (4, 72%), we can consider it acceptable for the evaluated method.
The constant SE cannot be corrected, but the proportional SE can be minimized changing the calibrators or the process of calibration. 
Background-aim
Quality indicators concerning haemolysis in pre-analytical processes are contemplated in consensus documents nowadays. Several of these documents propose a maximum level of 0.5 g/L as a landmark to establish the quality indicator. This cut-off point may be too high to be able to evaluate the haemolysis.
Our hospital receives samples from all over the province, which means there are several collection points which need to be evaluated. We try to obtain a way to find a suitable indicator for each laboratory.
Our aim is to establish cut-off points in the level of haemolysis to serve as internal quality indicators, taking the clinical significance of ananalytes into account.
Methods
As a starting point, haemolysis in our laboratory was assayed to determine the cut-off points of each analyte, according to the recent documents about harmonization. We studied both the analytical and biological variabilities, establishing three intervals for each parameter (1. below the analytical cut-off, 2. between the analytical and biological cut-off and 3. over the biological cut-off).
To perform the study, we built a database of 28475 samples of patients from the 40 collection points in our province (labeled alphabetically from A to AN). These laboratory requests include potassium (K), lactate dehydrogenase (LDH), folic acid (FOL), aspartate aminotransferase (AST) and alanine aminotransferase (ALT). We calculated the percentages of samples cointained in each of the three haemolysis intervals for the five parameters.
Results
For LDH, we found out that, being the average result in the second interval around 10-11% for most of the collection points, the percentage of some of them exceeded this value (AA: 27.38%, AB: 28.31%, AI: 35.08%, J: 35.8%, S: 41.46%). The results for K are quite the same, as the intervals are similar to those of LDH. The cut-off points of FOL, AST and ALT are higher, so they provided no successful way to filter the samples.
Conclusions
Haemolysis levels for LDH and K in the second interval are good indicators, as they are affected soon by increased levels of haemoglobin. This kind of study can lead to improvements in the performance of those collection points which need it, applying the corrective measures considered. 
Background-aim
Haemolysed specimens delay clinical laboratory results, proliferate unnecessary testing, complicate physician decisions, injure patients indirectly, and increase healthcare costs. In vitro hemolysis is a more frequent phenomenon compared to in vivo and occurs from poor sample collection. This causes unnecessary sample rejection and thus poses a major challenge in hospitals. According to American Society for Clinical Pathology (ASCP), a hemolysis rate of 2% or less is considered the benchmark of best practice.
Our objective was to perform the first audit of sample hemolysis rate in our 3-year old general hospital. Locations with higher than acceptable haemolysis rate will be highlighted and communicated to the respective unit leaders to generate awareness and identify process improvement opportunities.
Methods
All specimens analysed on our lab automation system over 9 months (1 Sep 2017 -31 May 2018) was extracted from Abbott Middleware -Data Innovations Instrument Manager. The data is then sorted according to the hemolysis index into non-hemolyzed, slightly hemolyzed, hemolyzed and severely hemolyzed categories using Microsoft Excel. The data is further categorized according to the ordering locations such as Emergency, Inpatient Wards, Outpatient Clinics and Intensive Care.
Results
A total of 211,891 sample data were collected and analysed. We noted 23,272 samples were hemolyzed giving an overall hemolysis rate of 11%. The overall hemolysis rate ranged from 10.4 -11.8% throughout the study period. Our slightly hemolyzed rate ranged from 8.2 -9.1%, whereas hemolyzed rate ranged from 2.1 -2.6%. The grossly hemolyzed rate ranged from 0.15 -0.21%. With regards to the ordering locations, we found the hemolysis rate to be highest from Emergency (12 -17%), followed by ICU (9 -15%), Inpatient Wards (10 -13%) and Outpatient Clinics (6 -10%). In terms of absolute number, the most hemolyzed samples come from Inpatient Wards (56%), followed by Outpatient Clinics (34%), Emergency (6%) and ICU (4%).
Conclusions
Our findings were consistent with other published data showing Emergency department hemolysis to be much higher than the ASCP 2% benchmark. However, we were concerned to discover similarly unsatisfactory hemolysis rate across all locations. Further analysis showed with the exception of the staff clinic, all other inpatient wards and outpatient clinics were unable to meet the desired benchmark. Although we were somewhat comforted that grossly hemolyzed specimens, which posed the greatest challenge to interpretation of patients' results, was at a much lower rate of about 0.2%, we acknowledged there is abundant room for quality and process improvement. 
Background-aim
Inflammatory processes, neoplastic alterations or immunological disorders can be diagnosed and followed by quantification of the corresponding plasma proteins. These proteins are called acute phase proteins and among them are ceruloplasmin, la1-antitrypsin or haptoglobin as positive acute phase proteins or prealbumin as a negative acute phase protein.
The objective was to compare the results obtained from ceruloplasmin, 〈1-antitrypsin, haptoglobin and prealbumin in two teams in order to substitute one method for another in our hospital.
Methods
We analyzed, consecutively and in parallel, 100 serum samples from hospitalized patients, outpatients and primary care. The samples were processed in parallel and to minimize the preanalytical error, the analysis was carried out in the two teams following a sequential order: first they were processed in the BNII System analyzer (Siemens) (which uses nephelometry as a measurement method) and subsequently in the Cobas 8000 analyzer (Roche) (immunoturbidometric method)
The correlation between the two methods was established with the Pearson coefficient (r). Linear regression was also obtained by Passing-Bablok, and differences were assessed with a Bland-Altman scatter plot, as well as their respective 95% confidence intervals (CI).
Results
The comparison included the folowing results: the correlation coefficient was 0,9476 (0,9221 a 0,9650) for ceruloplasmin, 0,9535 (0,9308 a 0,9688) for prealbumin, 0,3262 (0,1334 a 0,4953) for 〈1-antitrypsin and 0,9800 (0,9700 a 0,9868) for haptoglobin.
Conclusions
Based on the obtained values we can conclude that there is a good correlation between both instruments for all parameters evaluated except in the case of 〈1-antitrypsin, so it would be necessary to apply a change in the current reference values to minimize the systematic error. 
Background-aim
Haemolysis is an important interference factor that has to be considered as a security patient problem. It might lead to false laboratory results, plus might need to repeat phlebotomy and cause a delay in completing the laboratory analysis. At our laboratory, we measure the haemolysis index (H-index) via an automated system (Cobas6000, Roche Diagnostics). Measuring the percentage of samples that present haemolysis is one of our quality control indicators. The H-index is assessed with bychromatic measurements at 570/600 nm and is reported in arbitrary units. At the Consorci Sanitari de Terrassa, the prevalence of samples with haemolysis is higher than the other two hospitals that we work with (on average 11% during 2018). Causes for haemolysis are diverse and can occur at many points during sample processing, therefore a multidisciplinary approach has been used to review them.
Methods
An intern and extern serum index quality control was measured on a weekly and monthly basis respectively. At the laboratory, the centrifuges have been re-calibrated and centrifugation conditions have been reviewed (Heraeus Megafuge1.0). In collaboration with the Emergency Department (ED) and the Intensive Care Unit Department (ICU), the effect of the pneumatic tube system transport has been studied. Blood samples were transported from the ED and ICU to the hospital laboratory manually by hospital staff (60 patients for ED and 90 patients for ICU) or with a pneumatic tube system (98 patients for ED and 180 patients for ICU). The H-index studies were performed on the blood samples and compared between the different methods of transport. Finally, the phlebotomy technique was observed at the ED (9 blood extractions).
Results
The blood samples that were transported manually had a lower haemolysis frequency than those transported by pneumatic tube (13% less at the ED and 6% at the UCI). Some aspects of the phlebotomy technique could be improved (sample homogeneization, patient identification etc).
Conclusions
We observed a higher haemolysis frequency when the samples are transported by pneumatic tube compared to those transported manually. To reduce the impact of the transportation via pneumatic tube system, padding for the containers has been implemented. Also, nurse training in phlebotomy planned. 
Background-aim
Because the HDL cholesterol (HDL-C) test is used to predict the risk of cardiovascular disease, its accuracy is very important. We participated in the accuracy-based proficiency tests (ABPT) program of CDC LSP, CAP ABL, Korea Institute of Clinical Quality Assurance, for the evaluation of metrological traceability during geological surveys. The accuracy criteria for all the programs were fulfilled, but a positive bias of 3 -5% was observed for HDL cholesterol, and there was a bias difference in each calibrator lot. Hence, we tried to reassign the value of the calibrator using the NIST SRM (Standardized Reference Material), and evaluated whether the HDL-C test bias (%) was improved.
Methods HDL-C tests were performed using the Hitachi 7600-210 (Hitachi, Japan) analyzer using Cholestest N HDL (Sekisui, Japan) reagents and calibrated with Cholestest N Calibrators. The analyzer was calibrated using two-level NIST SRM 1951c materials, whose concentrations were 41.0 ± 0.9 mg/dL and 64.9 ± 1.7 mg/dL. The original calibrator (concentration: 58.2 mg/dL) was measured 10 times to calculate the reassigned value. Fourteen standard materials provided by the Korean CDC (KCDC) were analyzed in the system calibrated using the original and reassigned calibrator values. Additionally, the concentrations of LSP materials from US-CDC were measured and compared with the reference values of LSP materials.
Results
The mean reassigned values of original calibrator using NIST SRM level I, level II, and both level I / II were 56.6, 53.7, and 54.7 mg/dL.
When the standard materials provided by KCDC were analyzed, the mean bias (%) of the results using 3 reassigned calibrator values and those using original calibrator value were 1.8%, -4.8%, 0.2%, and 6.8%. The mean bias (%) of the results using reassigned calibrator values decreased from 4.1% to -1.0%, as compared to those using original calibrator value, when the three LSP materials from US-CDC were analyzed. The trends of HDL accuracy-based proficiency tests shifted from a positive bias to negative bias, as the reassigned calibrator values were applied.
Conclusions
The bias (%) from the target value in the HDL-C test was improved using the reassigned calibrator values obtained using NIST SRM. However, it is necessary to reset the calibrator value if the calibrator lot has changed. 
Introduction
Adrenocorticotropic hormone (ACTH) is sensitive to temperature and observation timing. The pre-analytical stability of ACTH was carried out in two groups of patients; one cohort of patients comprised of healthy volunteers, whilst another cohort included patients with renal failure and Adison disease. The impact of observational timing and the significance of plasma separation from formed elements after centrifugation was assessed.
Methods
During the three month a total of 24 patients were analyzed using Electrochemiluminescent immune assay (ECL) , One cohort of patients included 10 volunteers , whilst another the total of 14 patients: 9 patients with renal failure and 5 patients with Adison disease. Two blood samples were obtained from both cohort of patients. Specimen were immediately centrifuged after blood collection. The pre-cooled sampling tubes were used. The samples were analyzed at two points: immediately and after 2 hours of storage at 22C temperature. Centrifuged blood samples (12 sample) was kept in K3 -EDTA sampling tubes , whilst some plasma (12 sample) was moved into clean tubes .The content of ACTH was measured in both type of tubes -immediately and after two hours.
Results
The concentration level of ACTH kept in K3 -ETDA plastic tube has decreased between initial measurement and measurement taken 2h post centrifugation by 2.5%.On the other hand, neither time nor temperature had any effect on hormone concentration levels kept in clean tubes. The difference in change between these two groups was 15 %.
Conclusions
Preanalytical stability of ACTH is effected by observational period after centrifugation and separation of aliquots within K3 -EDTA plastic tubes post centrifugation. 
Methods
The production of CRMs for protein IVD is a challenging process which requires investigations on several parameters such as the availability of raw materials, commutability, stability, the level of the analyte of interest, and the strategy for assigning a certified value. The JRC develops several CRMs in close collaboration with the IFCC working groups.
Results
To support measurement standardisation of biomarkers for the early detection of Alzheimer's disease, the JRC released a panel of three pooled liquid frozen cerebrospinal fluid materials with different levels of amyloid-ß 1-42 (Aß1-42). The CRMs were characterised with reference methods based on isotope dilution mass spectrometry and the certified Aß1-42 mass concentrations with the associated expanded uncertainties were 0.45 ± 0.07 ⎧g/L in ERM-DA480/IFCC, 0.72 ± 0.11 ⎧g/L in ERM-DA481/IFCC and 1.22
In the field of autoimmune disorders the CRM ERM-DA483/IFCC was produced from a plasmapheresis sample of a patient diagnosed with vasculitis. This material was certified for the mass concentration of the immunoglobin G proteinase 3 anti-neutrophil cytoplasmic autoantibodies (IgG PR3 ANCA) and the certified value with the associated expanded uncertainty was 270 ± 29 mg/L.
Building on a long tradition in the development of CRMs for the catalytic activity concentration of enzymes, a new CRM for pancreatic amylase will be produced. As a first step in the process a commutability study was performed on five candidate materials. The outcome of this study showed which matrix composition is the most suitable for the new CRM to ensure its commutability for several of the routine IVD methods.
Conclusions
The JRC continues the development of new CRMs for biomarkers in various clinical fields including Alzheimer's disease, autoimmune disorders and cardiovascular diseases. 
Background-aim
Until recently about 10 diagnostic laboratories in our hospital used the same Laboratory Information System (LIS; GLIMS8). Because each laboratory had set up its own LIS, there was no uniformity and no exchange of specimens across the local lab departments was possible. Creating a common LIS with uniform architecture that enables sample & data logistics across the lab departments and guarantees complete sample track & trace for all labs was necessary to support the recently implemented Total Lab Automation in the complex clinical lab environment of an academic hospital.
Methods
It was decided to configure a whole new LIS, i.e. GLIMS9, which supports it all.
Results
Regarding the architecture of the LIS, both specific and general requirements were formulated. Major starting points were: middleware is not allowed unless there is added value for patient diagnostics; establishment of the Master-Slave concept, with the LIS as master and automated analyzers and track system as slaves; full track & trace on samples along its entire hospital trajectory; a central reception for all samples; a LIS configuration which reflects the actual routing of samples and processes in the total test process. An entirely new aspect in the setup of the LIS as Master was the management of a flexible track system connected to multiple preand post-analytical modules, and to several 24/7 analyzers. Important in the configuration of the middleware of the track was to keep it manageable. In the LIS over 10,000 tests were configured for all laboratories, with most of the samples being routed via the track. By using 'group codes' for tests where the routing on track is identical the configuration was simplified, resulting in about 1,000 tests configured in the middleware. Beyond the GLIMS redesign, the entire specimen request process, from digital order management in the Hospital Information System (HIS) till reporting of the test results in the HIS, was reconfigured and simplified. Other improvements were synchronization of the phlebotomy sampling time to allow accurate calculation of Total Turn-Around-Times and registration of nonconformities near the patient.
Conclusions
We conclude that successful Total Lab Automation demands a holistic approach, including LIS and HIS order request redesign. 
Background-aim
Haemolysis is the most common preanalytical error and leading cause of sample rejection. In order to decrease proportion of haemolysed samples, all potential contributors to haemolysis have to be controlled. In this study we aimed to investigate the possible association between sample type and haemolysis index.
Methods
Information on sample type and haemolysis index (H) was collected retrospectively from laboratory information system for all samples admitted at the biochemistry department in 2018. Sample type was classified as follows: VS (venous serum with clot activator), OP (FX sodium fluoride/potassium oxalate plasma), HP (lithium heparin plasma), EP (K2EDTA plasma) and CS (capillary serum with clot activator); all sampled in VACUETTE®, Greiner Bio-One, Kremsmuenster, Austria. H index was measured on Architect c8000 (Abbott Laboratories, Abbott Park, Illinois, USA) according to manufacturer's declarations. Samples were considered haemolysed if H index was N 0.5 (free Hb N 0.5 g/L). Difference in proportion of haemolysed samples between sample types was tested using chisquare test. P level b0.05 was considered statistically significant. 
Results

Out
Conclusions
The highest proportion of haemolysed samples was identified for capillary serum and oxalate plasma samples. Since oxalate plasma is used exclusively for glucose measurement and glucose is not sensitive to haemolysis interference, this finding doesn't require corrective actions. Problem of poor quality of capillary samples on paediatric and neonatology ward, on the other hand, requires urgent targeted efforts to reduce haemolysis. 
Background-aim
Natriuretic peptides [B-type natriuretic peptide (BNP) and Nterminal pro-BNP (NT-proBNP)] are useful biomarkers for diagnosis and prognosis of heart failure (HF). Stability of BNP assays must be examined, because there appears to be assay dependence, according to IFCC recommendations. Due to results reported about the BNP stability in frozen samples are controversial, the purpose of this study was to evaluate its stability in frozen plasma EDTA samples (-20°C) after a period of 30 days, without the addition of protease inhibitors, measured with a Lumipulse G BNP assay.
Methods
Blood samples were drawn into blood tubes containing ethylenediaminetetraacetic acid (EDTA), in two groups: group A, including 6 apparently healthy individuals, and group B, including 5 patients admitted to the Internal Medicine Department with HF. After centrifuging immediately, baseline plasma BNP levels were assayed within 30 minutes from blood collection and one aliquot was frozen at -20°C until tested 1 month later. BNP levels were measured on a LUMIPULSE G 600II analyser (Fujirebio), based on a chemiluminiscence immunoassay.
A change was considered significant when percent deviation (PD %) from baseline BNP level, defined as 1.65*CVA (analytical variation coefficient), was higher than 4.8% and 4.1% in groups A and B, respectively. Analysis of results was performed according to the criteria proposed by the SEQC-ML. Statistical analysis were performed using SPSS v. 21.0.
Results
Baseline BNP levels ranged from 4.5 to 13.6 pg/mL [mean (standard deviation (SD): 10.1 pg/mL (3.5)] in group A and from 65.3 to 1598.6 pg/mL [mean (SD): 606 pg/mL (546.5)] in group B.
At -20°C, BNP levels remained stable within 30 days from collection until measurement in both groups. PD for samples at -20°C was -4.7% in samples of patients with physiological BNP levels (group A) and 3.4% in samples with pathological BNP levels (group B).
Conclusions
BNP levels in frozen plasma samples, without protease inhibitors, remain stable at physiological and pathological levels for up to 1 month from collection, as manufacturer recommends. Our study support that freezing of plasma samples is an alternative solution when BNP cannot be measured in the first hours from blood collection. 
Background-aim
The main objective of the clinical laboratory is to provide results of clinical utility, so it is essential to demonstrate the comparability of the results whenever an analyte can be measured in more than one analytical system as in many laboratories, which use different instruments in series for the determination of the same parameter. They must ensure at all times the interchangeability of the results over appropriate intervals, to ensure correct interpretation.
Verify the comparability of results between 3 HPLC analyzers, for direct quantification of HbA1c.
Methods
Based on the EP31-A-IR protocol of the Clinical and Laboratory
Standard Institute (CLSI), the test was performed on 3 HA8180 analyzers (Menarini, Akray) with 2 analytical series in which patient samples were used at representative values (sample A and sample B) for the evaluation of HbA1c. The 2 levels of internal control (QCI) supplied by the manufacturer were used as control material, ensuring its commutability at all times.
Results
The results for samples 1 and 2 analyzed in the 3 analyzers shows that the number of replicates required based on the calculated parameter was 15. The acceptability criteria was based on biological variability (CVwithin-subject) of the HbA1c in healthy individuals. The analytical quality specifications for the allowable difference between analytical systems in our laboratory organization should be set at desirable levels of 2/3 CVwithin-subject (CVwithin-subject*2/ 3=1.85*2/3=1.23%).
The sample A showed an average of the results for each instrument of 5.78% and the sample B showed an average of 10.83%. And the calculations corresponding to range and range rejection limit were 0.00764 and 0.061 respectively for the sample A and 0.02124 (range) and 0.1144 (range rejection limit) for the sample B.
Conclusions
In this parameter studied, the calculated range has been lower than the range rejection limit, so that the 3 instruments provide results comparable to the evaluated concentration and the comparability of the methods is considered acceptable, given the known underlying bias between the analyzers. 
Background-aim
Viral load (VL) is recommended as the preferred monitoring approach to determine the performance of Combined Antiretroviral Therapy (cART) in HIV-infected individuals. According to the Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection (ZCG) 2018, the first VL is done at 6-months post-initiation, and if VL is less than 1000 copies/ml, 12-months post-initiation and every 12 months, if it remains below 1000 copies/ml. VL monitoring for HIV-infected pregnant and breastfeeding women is done at baseline for known HIV positives. Henceforth, VL to be done every 6 months during pregnancy and breastfeeding period. However, if VL is greater than 1000 copies, a repeat VL is done at 3 months following enhanced adherence counseling, until suppression is achieved or the cART regimen is switched.
Early Infant Diagnosis (EID) of HIV is done in children below 24 months of age born from HIV-positive mothers. In Northwestern province, like Viral Load, EID is done at the Polymerase Chain Reaction (PCR) Laboratory at Solwezi General Hospital through the use of Dry Blood Spot (DBS) specimen. According to ZCG 2018, Nucleic Acid Test (NAT) is a preferred test for EID because NAT is a Point of Care Test (POC) and can be accessible at the point of service delivery and offer same-day results. Nevertheless, due to the unavailability of POC NAT, DBS specimen are sent to the PCR Laboratory for processing. DBS specimen are collected from HIV Exposed Infants (HEI) at birth, 6 weeks, 6 months, 9 months, 12 months, 18 months, 24 months and 6 weeks after complete breastfeeding cessation.
All these DBS and VL specimen are sent to the PCR Laboratory for processing. The turnaround time for these tests results is crucial in management of clients, more especially the HEIs. This is because clinicians' decisions are solely dependent on these results. The objective of this study was to assess the impact of electronic VL/EID results transmission in reducing the turnaround time in Northwestern province of Zambia.
Methods
Direct inward system access (DISA) service at the PCR Laboratory was used to populated VL/EID results recently processed. The password encrypted Excel Workbooks for both VL and EID results raised from the DISA service were shared with responsible Clinicians and Data Entry Clerks (DECs) via email and WhatsApp group platform. Unsuppressed VL and DBS Detected spreadsheets are separated and colored red for quick intervention.
Results
From an average turnaround time of 30 days when using the motorcycles, the turnaround time of electronic results reduced to less than 5 days -to allow sample preparation and processing. Otherwise, electronic results transmission can take less than 1 hour.
Unlike hard copy transmission of VL/EID results via motorcycles, using the electronic results enabled the clinicians and clients to immediately have access to the results soon after the specimen is processed and authorized -reducing the turnaround time to the shortest possible time.
Conclusions
Electronic transmission of VL/EID results system greatly reduced the turnaround time and allowed prompt informed decisions to be made by clinicians. It is recommended however, that both methods of results transmission be used concurrently as they supplement each other very well. 
Background-aim
One of the leading source of errors which impact clinical laboratory results encounter at the pre-analytical phase of testing. Factors as sample collection, improper handling, drugs, hemolysis, lipemia may influence the test result. Melatonin is a principal secretory product of the pineal gland. The hormone secretion is stimulated by darkness and inhibited by light so that is called "the hormone of darkness". The data about analytical interference of hemolysis, bilirubin and triglycerides on serum melatonin concentrations are scarce. The aim of our study was to evaluate the effect of this factors on serum melatonin concentrations.
Methods
Venous blood samples were collected from five clinically healthy subjects. Two tubes venous blood were taken from each patient. The first tube was centrifuged and serum was obtained. Serum was spiked with increased concentrations of bilirubin (Bilirubin standard, cat. N°S-106, Cormay) and triglycerides (Triglycerides standard, cat N°S-113, Cormay). For hemolysis making, the second tube was mixed for 30 min. (Schüttelfrequnz, Germany). Free hemoglobin was measured on spectrophotometer (Specol 11, ref. range: up to 40 mg %). Measurement of serum melatonin was performed using ELISA kit (IBL, Hamburg, Germany) and Sirio S microplate reader (SEAC, Italy). Results were compared to baseline values and bias (%) was calculated.
Results
Serum with hemolysis showed decreased melatonin concentrations in all tested samples (bias: -59.5 --85.4%). The bilirubin interference is: at spiked concentration with bilirubin 8.267 ⎧mol/l -bias + 2.95% and with bilirubin 15.782 ⎧mol/l -bias + 17.71%. Triglycerides also allowed positive interference on the melatonin concentration: bias + 2.58 % (0.238 mmol/l) and + 16.61% (0.454 mmol/l).
Conclusions
Our results show that hemolysis, triglycerides and bilirubin affected serum melatonin concentrations. Hemolysis in specimen is a negative interferent, and bilirubin and triglycerides are positive interferents. Evaluation of the interference of this factors will help for better clinical interpretation of serum melatonin results. 
Background-aim
The laboratory division at the Meir Medical Center provides a wide range of laboratory services to all medical center departments, while continuously striving to improve its performance. In 2018, we initiated and carried out the Digital Laboratory project in the Internal Medicine departments. The main objective was to replace the existing process of filling out test order forms manually by implementing a controlled, electronic system to decrease errors, missing information and processing time in the labs. Planning and initiating the new process involved verity of hospital units, including information management, procurement, logistics, nursing and laboratory. Several stages were required: acquiring equipment, revising lab software settings and building new work processes in the labs and in inpatient departments.
The aim of the study was to evaluate the success of the project by measuring improvements in lab services to the departments included, based on key parameters of sample rejection, turnaround and processing time.
Methods
We have based the analysis on data collected from our laboratory information system, regarding these key parameters.
Results
We measured a 5% decrease in internal medicine departments rejected samples, compared with the corresponding period in 2017, before the project was implemented. Turnaround time of chemistry and hematology tubes, showed 40% of tubes were handled by the lab earlier in the morning, compared to corresponding period in 2017. In addition, more efficient performance time was measured for several routine laboratory tests, and successful performance time of 65 minutes for urgent marked tests in the system, which accordingly require faster execution in the busy morning hours.
Conclusions
The Digital Laboratory project considers to be a revolution in Meir Medical Center lab services and provides efficient and advanced service to the hospitalization departments. Our results indicate progress and improvement in the service, such as reduction in sample rejections, quicker receipt and performance of routine and urgent tests. The successful implementation of this process encourages us to extend it to additional departments, including emergency rooms and intensive care units. doi:10.1016/j.cca.2019.03.1521
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Reliable detection of kEDTA sample contamination requires a routine EDTA assay S. Whitehead, C. Ford, R. Gama Dept. of Blood Sciences, New Cross Hospital, Wolverhampton, UK
Background-aim
Potassium-ethylenediaminetetraacetic acid (kEDTA) contamination of serum samples is identified as unexplained hyperkalaemia and hypocalcaemia and if unrecognised may adversely affect patient care. We assessed the value of an EDTA assay in identifying kEDTA contamination and studied the effect in vitro EDTA contamination on surrogate serum biomarkers of EDTA contamination.
Methods
Serum spiked with k2EDTA plasma, to mimic sample contamination, was used to: 1) study its effect on potassium, calcium, zinc, magnesium and alkaline phosphatase and; 2) derive local cut-offs for classifying EDTA contamination as part of approach to identifying it in routine patient samples. Our current laboratory protocol for identification of kEDTA contamination based on measurement of serum calcium was then compared to that of EDTA measurement.
Results
An EDTA concentration of N0.19 mmol/L was associated with a significant change in serum potassium (increase of 0.54 mmol/L [11.9%]) and zinc (decrease of 71%); no significant reduction in measured calcium, ALP and magnesium was observed. The serum EDTA assay detected contamination (ε0.2 mmol/L) in 31/106 patient samples with hyperkalaemia (potassium ε 6.0 mmol/L), 20 of which were undetected by the current laboratory protocol.
Conclusions
Measurement of EDTA is necessary to reliably identify significant sample contamination from small amounts of k2EDTA and prevent mislabelling genuine hyperkalaemia as kEDTA contamination. Clinically significant sample contamination occurs from small amounts of kEDTA which cannot be reliably identified using surrogate serum biomarkers. Unexpected hyperkalamia and hypocalcaemia is commonly used to detect k2EDTA contamination however, our spiking data indicate that this will only identify gross contamination. Serum zinc has the potential for detecting low levels of EDTA contamination although this is prone to an acute phase effect. 
Background-aim
Gamma-glutamyl transferase (GGT) is routinely used as a highly sensitive marker of hepatobiliary disease, alcohol consumption and more recently as a predictive biomarker of cardiovascular events. In current practice, most laboratories measure the GGT activity on tube containing lithium heparin. Except that there is no evidence that GGT activity can be reliably determined with this anticoagulant. The purpose of this study is to evaluate the impact of the anticoagulant on the determination of GGT activity in blood samples.
Methods
Blood samples of 30 patients were collected in three types of tubes: dry tube, tube containing lithium heparinate and another containing dipotassium ethylene diamine tetraacetate (EDTA). The statistical analysis includes correlation studies, Bland Altman's analysis, as well as the comparison of biases to the analytical change limit (ACL).
Results
Results obtained on heparinized plasma are globally overestimated comparatively to the serum (p=0.001). Whereas, the results obtained on EDTA plasma are more comparable to those of serum (p=0.356). Taking the dry tube as a reference, the calculated bias for heparinized plasma (+49.55%) samples is larger than the ACL (5.24%), while the bias is about -13.40% for EDTA plasma samples.
Conclusions
Our results show that the determination of GGT activity must be done on serum samples. If ever plasma should be used, we recommend collecting specimens on EDTA anticoagulant. 
Background-aim
Adrenocorticotrophin (ACTH) is a very useful marker for the diagnosis of endocrine disorders. As a protein, ACTH seems to be degraded by the action of proteases. In order to maintain the preanalytical stability conditions, it is accepted to collect samples in a plasma K3EDTA tube and place it on dry ice immediately. A previous study suggests that aprotinin, a serine protease inhibitor, permits to enhance the stability of ACTH. Our laboratory uses K3EDTA + Aprotinin tubes for ACTH determinations in adults, and K3EDTA for paediatric determinations. Our main objective was to evaluate the ACTH behaviour in different storage conditions and the effect of the addition of this proteolytic enzyme inhibitor (aprotinin).
Methods
We collected venous blood specimens from 10 healthy volunteers at 8.00 a.m. From each subject, we collected 4 tubes: 2 K3EDTA, and 2 K3EDTA + Aprotinin. Specimens were immediately centrifuged (10 min; 4°C: 2000rpm; 22°C: 3000rpm). Each primary tube was then aliquoted in 5 tubes, having a total of 20 aliquots per patient. Each aliquot was left at 2°C to 8°C or at room temperature, during different periods of time (0, 2, 4, 8 and 24 hours), and then frozen at -20°C until analysis (Immulite 2000 XPi, Siemens). Samples were considered stable when they met the formula: Analytical CV% x 1.64 b 13.42. Student's t-test was used to compare all ACTH concentrations by tube type, at each time point.
Results
A total of 200 aliquots were analyzed after thawing them at room temperature. Samples that remained at room temperature maintained the ACTH stability during 4 hours. Samples stored at 2°C to 8°C kept the ACTH stability during 8 hours. There was a loss of stability after the following hours at those conditions. Results were independent of aprotinin.
Conclusions
Storage conditions play an essential role to maintain the ACTH stability. There were differences between storage conditions, preferring to keep the tubes refrigerated for up to 8 hours until analysis. As no differences were seen among tube types, aprotinin seems to be not necessary, especially at 2°to 8°C storage and for costeffectiveness. 
Background-aim
The Alinity c system Sample Interference Indices method provides a more accurate and consistent method for interpretation of interferents than time consuming visual interpretation. The Alinity c HIL method uses specific wavelength pairs and an algorithm to provide a Sample Interference Index (HIL) that can correlate with sample interference due to turbidity, hemolysis and bilirubin present in serum/plasma samples. These values in combination with interference studies can be used to determine the potential for HIL interference for Alinity c clinical chemistry assays.
Methods
The HIL methodology will be described and discussed. The study followed CLSI protocol EP7-A2. Interferences were studied up to concentrations of 1000 mg/dL for hemoglobin, 1000 mg/dL for triglycerides, and 30 mg/dL for Bilirubin (unconjugated) in serum. Serial dilutions of the sample pools were analyzed in replicates of 4 on the Alinity c system. A cumulative summary was compiled of the Hemolysis, Lipemia and Icterus indices for about 80 Alinity c Clinical Chemistry assays.
Results
Using known concentrations of hemoglobin, bilirubin and Intralipid, the Abbott Semi-Quantitative Index (concentration in mg/dL) and Qualitative Index (Blank, 1+, 2+, 3+ 4+) were confirmed on the Alinity c system. Correlation studies show a linear relationship (r = 1.0) of the indices with increasing concentration of analyte. Using the HIL Qualitative Index scores combined with the specific assays interference results provided a guide to potential interferents for the Alinity c clinical chemistry assays. Approximately 50 of the Alinity clinical chemistry assay were not compromised using samples with elevated H, L or I index values (4+ estimates). However, accuracy of about 30 assays (example albumin) could be over-estimated in the presence of hemoglobin, Bilirubin and/or Lipemia denoted by H indices N/= 4+.
Conclusions
The Alinity c system provides a simple automated procedure for determining the sample indices (HIL) for patient specimens on the Alinity c system. These HIL values in combination with samples interference studies can be used to determine the potential for HIL interference in the Alinity c clinical chemistry assays to avoid misdiagnosis. 
Background-aim
Calcium, phosphorus and magnesium in urine can be required for the diagnosis of renal pathology. Hydrochloric acid (HCL) is a preservative avoiding the precipitation of calcium and keeping phosphorus in dissolution. Inserts indicate acid urines to analyze these ions, but it is tedious in clinical laboratories. Acid is a corrosive that need to be handled specifically. Most measurements in urine are required in no-acid urines. Acidifying urine means more containers, analysis time and storage space. Many laboratories use no-acid urines to analyze these ions. We study pH influence on the accuracy of analysis for these analytes. We evaluated stability after four and seven days from collection.
Methods
Fifty five urine samples were chosen without preservative and centrifuged at room temperature 10min 1760g. We prepared two aliquots with 1 mL, one acidified with 10 ⎧L HCL 20%. Both aliquots were processed in our laboratory accredited by UNE-EN ISO 15189:2013. Calcium, phosphorus and magnesium were measured. Aliquots were stored at 2-8°C until an analysis after four days and seven days.Calcium and phosphorus were measured on cobas 8000® c701 (Roche®) using NM-BAPTA assay and molybdate assay, respectively. Magnesium was measured on cobas 8000® c702 (Roche®) using xylidyl blue assay. Urinary pH was measured with pH strips Multistix® 10 SG Siemens and pH-indicator MColorpHast™. We used MedCalc® for Bland-Altman and PassingBablok between acid and no-acid urines and stability after four and seven days from collection.
Results
Calcium showed no systematic differences. Proportional differences were found between acid and no-acid, after four days in noacid, and after seven days for both urines.Phosphorus showed systematic differences in no-acid urines after four days and in both urines after seven days. Proportional differences were found between acid and no-acid urines, after four days and seven days in both urines. Magnesium showed systematic differences always. Proportional differences were found after four days in no-acid urines and after seven days in both urines.
Conclusions
The differences found between acid and no-acid urines are so slight that we can work with no-acid urines. Samples can be processed until four days post-collection without relevant effects on the stability Background-aim EDTA-dependent pseudothrombocytopenia is a rare phenomenon of in vitro platelet agglutination due to the presence of antiplatelet antibodies. In these cases, the peripheral smear must be observed in order to confirm the presence of platelet aggregattes. In addition, blood sample anticoagulated with sodium citrate is the most suitable sample for the platelet count.
The laboratory has the responsability of detecting these false thromcytobopenias, and reflecting this information in the laboratory report. Likewise, the clinician should consider this condition in order to avoid innecessary diagnostic tests and procedures with the aim of preserving preserve patient safety.
Methods
A 8-year old boy was referred to paediatric onco-hematology for presenting a two-year evolution thrombocytopenia with a platelet count below 20 . 10^3/μL. He did not have a significant past medical history, besides his familial hypercholesterolemia, and his clinical examination was unremarkable.
The inicial working diagnosis was of a PTI and an aspiration biopsy of the spine was made. There were no significative anomalies in the sample obtained. In that moment the clinician realized that in all the previous laboratory reports, there was a commentary on the platelet count remarking the presence of plentiful platelet aggregates. The hemogram and the blood smear was repeated, and a platelet count was made in a sample with sodium citrate, obtaining a normal count (160 . 10^3/μL).
Results
According to the WHO, patient safety is the absence of preventable harm to a patient during the process of health care and reduction of risk of unnecessary harm associated with health care to an aceptable minimum.
The clinic laboratory works an importan role over patient safety, not only in the analytical and preanalytical phase, but also in the -sometimes forgotten-post-analytical phase. Likewise, we should make sure our laboratory reports are understood by clinicians and consider offering complementary tests if necessary.
Conclusions
From the laboratory, we should enhance our relationship with clinicians trying to avoid misunderstandings as the reflected in the case report. It should be remainded them that in those cases with EDTA-dependent pseudothrombocytopenia, a blood smear is mandatory to confirm platelet aggregates and that the evolution of the platelet count requires a sample with sodium citrate. 
Background-aim
During the last years the assistance activity and the demand for laboratory tests have increased, without being associated with an increase in economic resources. That makes it necessary to use management tools, especially in expensive tests such as procalcitonin, a useful biomarker in the diagnosis of sepsis and infections in other locations.
In our laboratory, procalcitonin was introduced in April-2013, restricted to Paediatrics, Intensive and Resuscitation. It was possible to apply for any clinician, increasing their demand and generalizing in practically all areas, with 8,793 requests in 2017, more than a half from services not agreed at the beginning. After this increase, a preanalytic demand modulation protocol was established.
Methods
A request filter was made. In the computer system procalcitonin is an open test. Upon request, a pop-up window opens: "The determination of procalcitonin is useful for the diagnosis and monitoring of the septic patient. Do you want to continue the application? ", Once accepted, a drop-down will appear to choose a reason for request:" suspicion of sepsis, treatment control in septic patients, fever and leukocytosis without focus, others "
Results
After the implementation of this filter, half of determinations are made. The majority of Intensive, Resuscitation, Internal Medicine and Geriatrics, Pediatrics, Urgencies and Hematology, although there are of all areas. The most requested request motive was "septic patient control", followed by "suspicion of sepsis"
Conclusions
In recent years, the need to assume has arisen the responsibility of reviewing and evaluating analytical determinations by laboratory professionals. A more unnecessary requests, higher risk and more chances of error.
The best strategies for the control of the demand of testing are the act when the requesting doctor makes the request.
After detecting the high demand for procalcitonin, the need arises for its modulation without impairing the attention to patients and clinicians. A modulation of the preanalytic demand is decided, which allows the application with clinical justification, since it is handled by most of the units. 
Background-aim
Nowadays serum indices (HIL), hemoglobin (H-index), icterus (Iindex) and lipemia (L-index), have been automatized in many laboratories for evaluating the sample quality. Data of HIL indices measures condition the rejection or acceptance of laboratory test results. However, HIL indices are susceptible to interference and the laboratory must ensure the results accuracy so that patient safety won't be compromised.
Methods
A specific protocol was computerized in the laboratory information system according to the results of an internal interference study performed following CLSI recommendations in a Dimension EXL system (Siemens Healthcare SLU). For the indices estimation, the analyzer adds water to 20 ⎧L of sample and the indices measurement wavelengths are 405 nm (hemoglobin), 452 (bilirubin) and 700 (lipemia/turbidity).
Results
After protocol implementation, direct observation detected icteric samples (I index N or=3, equivalent to a bilirubin concentration from 5 to 20 mg/dl) leaded to a hemolytic index N or = 3 (equivalent to a hemoglobin concentration from 50 to 200 mg/dl) without hemolysis. Lactate dehydrogenase, aspartate aminotransferase, potassium, sodium and creatinine were incorrectly rejected or flagged with a possible hemolysis interference comment. The algorithm was modified and a flag is now displayed with a recommendation for hemolysis visual inspection when H index is suspected to be falsely increased due to high bilirubin.
Conclusions
Although modern analyzers are able to identify HIL interference much more accurately than the traditional visual approach, indices overlap may exist and visual inspection may still be required.
HIL indices interferences are manufacturer and analyzer dependent, so every laboratory must be aware of the interference and the mechanism in order to establish the suitable strategy for it detection and correction. 
Background-aim
Pre-analytical phase standardization is a main requirement for the clinical implementation of biomarkers and, specifically, of circulating miRNAs. miRNAs are present in blood as free (e.g., associated with argonaut protein, low-density lipoproteins) and microvesicle-associated forms. Based on their release, free-circulating miRNAs are considered biomarkers while microvesicle-associated miRNAs mostly carry out the role of hormone-like compounds.
Aim of this study was to evaluate the effects of common preanalytical variables on detectability and stability of a panel of microvesicle-associated and free circulating miRNAs.
Methods
Venous blood from 10 male volunteers was collected into K2EDTA tubes and plasma preparation tubes (PPT), containing a double amount of EDTA. Plasma was obtained by centrifugation according to the manufacturer's indications (1-K2E, PPT), while an aliquot of K2EDTA plasma was further centrifuged (2500g, 15min, room temperature) to deplete the platelets (2-K2E). Samples were immediately frozen or stored for 24h at either room temperature or 4°C. The microvesicle-associated and free circulating fractions of 179 miRNAs was assayed by RT-qPCR.
Results
Detectability of free miRNAs was greater in PPT samples than in 1-and 2-K2E samples; particularly, 2-K2E samples displayed the lowest detectability over all the conditions. Detectability in 1-K2E samples was mostly affected during storage, regardless the condition, while in PPT sample miRNA expression levels remained stable. Also for the exosome-associated miRNA fraction, samples collected in 2-K2E displayed the lowest detectability and stability but, in this case, the storage conditions had comparably no effects on miRNAs stability in PPT and 1-K2E samples, although it resulted slightly improved in 1-K2E samples.
Conclusions
Taken together these results indicate that blood collection in PPT, i.e., higher amount of spray-coated EDTA, guarantee a greater stability for free-circulating miRNAs (i.e., the biomarker-like fraction), compared to K2E samples, and also for microvesicle-associated miRNAs (i.e., the hormone-like fraction) the performance of this tube are good. On the contrary, a stepwise centrifugation strongly affected miRNA detectability and stability of miRNAs and, therefore, it may not be applied in miRNA testing. 
Background-aim
The physical activity status represents an important pre-analytical variable that might be considered in a clinical setting especially in the case of the measurement of those biomarkers whose circulating levels are strongly modified by chronic training. Hence, sedentary and highly trained subjects are thought to display really different circulating miRNA profiles. However, the use of circulating miRNAs as biomarkers is still limited by the lack of standardized post-analytical data processing. This work aimed at comparing the effect of different normalization approaches on RT-qPCR data. In order to identify the most appropriate strategy to obtain the most reliable results, normalization methods based on endogenous and exogenous miRNAs were assayed in order to evidence the differences in the expression level of free-circulating miRNAs between sedentary and highly-trained subjects.
Methods
Circulating miRNAs were extracted from plasma of 10 sedentary and 14 trained males. A panel of 179 miRNAs (i.e., the most represented in blood) was assayed by RT-qPCR. The relative expression of each miRNA was calculated by the 2-⊗⊗CT method using, as normalizer, the average value of all expressed microRNAs, the averaged expression values of the most stable endogenous miRNAs, the single most stable miRNAs, and exogenous oligonucleotides. The identification of the most stable miRNAs were performed using the NormFinder algorithm, ranking the miRNA based on their expression stability.
Results
Different normalization methods lead to different, and sometimes contrasting, results. Among the endogenous-based methods, normalization on the single miRNA hsa-miR-320d resulted the most appropriate strategy giving the lowest technical variability among the replicates and the best method to highlight the existing differences in the miRNA profile between the two sample populations. On the contrary, exogenous oligonucleotides resulted the worst normalization methods.
Conclusions
This study highlights the importance of an accurate choice of the appropriate normalization strategy for each experimental setting in order to avoid misleading interpretation of RT-qPCR data. 
Background-aim
If a PTS (Pneumatic Tube System) is used to send Heparin tube (HT) samples to laboratory then pre-analytical complications, such as debris, fibrin or foaming and bubbles may occur. These may interfere with analyses and require extra manipulation and reanalysis, causing an increase in turn-around time and contamination. BD-Barricor® tubes (BT) are a heparin plasma tube based on using a mechanical barrier to separate the cellular material from the plasma. BT was compared to non-gel HT and non-gel serum Clot Activator Tube (CAT) in an emergency biochemistry laboratory department, including the effect of tube type on hyperleukocytosis interferences. The aim is to provide an alternative separation method for laboratories that do not wish to use tubes with gels.
Methods
Blood was collected from 197 patients in four departments of Lille University Hospital and transported by PTS. Samples were collected into 3 tube types: BT, HT without gel and CAT and were analyzed simultaneously. Pre-analytical issues were evaluated. A stability study was performed after 12h storage at RT without sealing. Hyperleukocytosis interferences were assessed in a patient cohort (N50x109/L).
Results
BT reduced bubble formation. For HT, poor stability was observed for glucose determination while a better stability was found for BT. This difference in stability might be accounted for by a better separation between plasma and cells thus reducing glycolysis by leukocytes. Interestingly, a significant decrease in hemolysis index was noticed for BT. CAT reduced hyperleukocytosis interference compared to HT. We hypothesized that the clot protects from release of cell contents and that the separator in BT might perform the same function. In patients with hyperleukocytosis, there may be a reduction in interference with BT tubes compared to HT tubes but this needs to be confirmed by further study.
Conclusions
The new BT offers advantages in terms of a reduction in the time spent on laboratory management, a reduction in pre-analytical issues, higher speed/lower time centrifugation and better stability. BT could be an alternative for laboratories that would like to gain the benefits of separator tubes but do not want to use gel-separator tubes. 
Background-aim
Sullivan Nicolaides Pathology receives and collects approximately 20,000 pathology samples per day from hospitals, GP clinics and community blood collection centres over an area in North Eastern Australia the size of Western Europe. In general only one serum (SST) and one EDTA tube are collected for each patient episode. The pre-analytical phase of the pathology testing cycle is a significant source of laboratory error. Pilot studies in 2016 demonstrated that significant resources were required for pre-analytical troubleshooting including sample recollection and erroneous results. The introduction of a GLP track for distribution of samples for automated biochemistry has further highlighted the need to identify samples which are unsuitable for immediate loading onto a track. Identification of the major sources of unsuitable samples will allow determination of strategies to minimize unsuitable samples which in turn will lead to the reduction of pre-analytical laboratory errors. This study provides data on unsuitable samples from a private community reference laboratory.
Methods
Further studies identified that 5.4 % of samples referred for automated biochemistry could not be immediately loaded onto a track and required human intervention. Centrifugation for biochemistry samples is usually performed at the point of sample collection. Statistics on the number of samples requiring human intervention were collected for the 12 month period February 2018 -January 2019.
Results
Overall 3.8-5.5 % of all samples required human intervention. The main causes (monthly range; lowest -highest) over 12 months were as follows: insufficient sample (2.3-3.1%); unspun tube (0.7-1.0%); tube re-spin (0.3-0.9%); and fibrin clot (0.3-0.8%).
Conclusions
These results have identified areas for further education of collectors to improve sample quality. Graphical KPI reports have been implemented for each phlebotomist throughout the practice. 
Background-aim
Kaizen methodology is a quality strategy based in continuous improvement by reducing waste (muda), eliminating unnecessary hard work and humanizing workplaces (gemba).
The aim of this study is to implement Kaizen methodology in a preanalytical area (9000 samples/day).
Methods
The methodology was implemented by performing the following steps: 
Conclusions
Kaizen methodology is a useful tool to improve workflows and utilization of resources and to increase efficiency. 
Background-aim
Sperm presence establishment in forensic casework demands operative preanalytical stage with maintaining stability of ProstateSpecific Antigen (PSA). The aim of the study was to investigate stability and activity of total PSA in dry sperm spots, extracted with deionized water in comparison with distillated water. Deionized water helps to minimize microbial contamination that could improve stability of the samples.
Methods
Semen of volunteers diluted in distillated and deionized water in proportions of 1+1 (high concentration) and 1+25 (low concentration) was put on sterile gauze (0.5 sm x 0.5 sm) in volume of 1 μL and dried in temperature 18-20°C for 3-4 hours. Samples were extracted with 100 μL of distillated and deionized water in +4°C for 18 hours. The extracts were aliquoted to five portions per each level of concentration and stored at +18-20°C during 6 hours. PSA amount was measured by an enzyme-linked immunosorbent assay method (ELISA) in the two obtained concentrations (26.3 ng/ml and 5.4 ng/ml) five times during one day. The average, within-and between series imprecision and percentage of lost PSA activity were calculated.
Results
The within series CV% was bigger for low concentrations PSA (pb0.05) for samples extracted by distillated water compared with deionized (7.8% and 4.0% respectively). Between-series variation was bigger for both levels of concentrations in samples extracted by distillated water (pb0.05): 28.3% and 13.2% for low and 15.2% and 6.7% for high concentrations respectively. Activity of total PSA were significantly decreased (pb0.05) in samples extracted by distillated water compared with deionized for low concentrations of PSA: 64.9% and 81.2% after 3 hours and 51.6% and 71.6% after 6 hours respectively.
Conclusions
Samples of semen on dry spots for testing of total PSA extracted with deionized water at room temperature (+18-20°C) are more stable compared with distillated water and could be stored up to 4 hour 30 minutes during working day while PSA extracts with distillated water could be stored no more than 1 hour 30 minutes. Thus implementation of deionized water for PSA extracts from semen on dry spots improves the quality of preanalytical phase. 
Background-aim
Although complement assays are now part of the routine immunological assessment in many fields of medicine, the results are very sensitive to pre-analytical handling. EDTA-containing collection tubes are known to stabilize the analytes and to make the results more reliable. However, reference intervals (RIs) for EDTA plasma samples have not previously been published. Thus, the objective of the present study was to determine RIs for classical pathway (CP50) activity and C3c, C4 and C1 inhibitor protein levels in EDTA plasma samples, using Optilite® reagents from The Binding Site Group Ltd.
Methods
We retrospectively evaluated a large cohort of patients attending our university hospital and known to be free of complementassociated diseases. The need for age partitioning was assessed and RIs were calculated for each parameter according to the Clinical and Laboratory Standards Institute's C28-A3c protocol.
Results
A total of 387 samples with assay data for CP50 activity and C3c and C4 protein levels were used to derive the RIs. These came from 307 adults (median (range) age: 47.7 (18-87.7) years) and 80 children (13.6 years (6 months-17.9 years)). A subset of this population also had assay data for C1 inhibitor protein (96 
Conclusions
We provide RIs for complement component assays in EDTA plasma samples. C1 inhibitor protein levels were linked to age, and so the use of age-specific RIs is mandatory. These RIs will be of value for the diagnosis of complement-related diseases and for the accreditation of laboratories. 
Background-aim
The aim of this study is to avoid eliminating results in patients with "in vivo" hemolysis (IVVH) and altered hemolytic index (HI) due to the algorithms applied currently to "in vitro" hemolysis (IVTH), using hemoglobin value.
Hemolysis is a common interference in the medical lab, and it can produce spurious results due to several mechanisms.
In order to systematize and standardize the actions related to the IVTH, automatic algorithms based on the HI has been developed in our lab. In this regard, results are informed with a comment if the interference is analytically significant and not informed if is clinically significant.
Because the idiosyncrasy of our hospital a strategy to inform results in IVVH is mandatory.
HI is not always altered in patients with IVVH. However, for those with HI above 0, the identification of the clinical situation is essential. From those, requests with a HI above 0 were selected (187 request from 78 patients) As a IVTH group, 906 request (807 patients) from the same period with a diagnosis non related with IVVH, apparently healthy and with a HI of 1 or above were selected.
Statistical analysis was performed by Stata. HI was performed by AU680 from Beckamn coulter.
Results
Hemoglobin in the IVVH group was 9.11 g/dL (8.8-9.42; 95% IC) and in the IVTH group 13.78 g/dL (13.69-13.88; 95 % IC). Differences between groups were significant (pb0.05).
Based on the promedio of hemoglobin in IVVH group, it was established 9.5 g/dl as a cut off to set up an alert during validation process. The aim of this alert is to identify IVVH and do not treat this patients as an IVTH, and therefore do not apply hemolysis algorithms.
A simulation was performed with all the requests from 2017 with an altered HI. And the cut off of 9.5 g/dL evidenced a sensibility: 88.5 % and a specificity: 64%)
Conclusions
The strategy has certain limitations, patient with transfusions has not been identified and we are not able to identify the 100% of the IVVH.
Patient with both IVVH and IVTH can not be identified in an isolated drawn, so if suspected in cases with HI above 1, new specimen need to be requested if possible.
It is a good strategy for patient safety in order to treat IVVH separately, with this strategy we would have detected 88% of HVVI with HIN=1. 
Background-aim
Hemogram analysis is frequently used in practice by clinicians of all specialities. In order to interpret the results of hemogram parameters correctly, it is necessary to know reference intervals (RIs).
Methods
Venous blood samples were taken from 286 healthy children (119 female, 167 male) at prophylactic medical examination. All samples were measured by a Sysmex XT-2000i analyzer. RI were calculated according to CLSI C28-A3 standard for the following parameters: leukocytes (WBC), absolute number of neutrophils (NEUT), lymphocytes (LYMPH), monocytes (MONO), eosinophils (EO), basophils (BASO), platelets (PLT), hemoglobin (HGB), erythrocytes (RBC), hematocrit (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red blood cell distribution width (RDW-CV), absolute reticulocyte number (RET), low fluorescence reticulocyte fractions (LFR), immature reticulocyte fraction (IRF). RIs are presented as 95% intervals (2.5th-97.5th percentiles), age is presented as medians (25th-75th percentiles).
Results
RIs were calculated in four age groups, month: "b12" -4(4-5), 12-60 -31(26-36), "60-120" -98(78-108) and "N120" -138(131-158). No age and gender differences had RIs of MONO (0.37-1.26) x109/L, BASO (0.00-0.05)x109/L, MCHC (320-353) g/L, RDW-CV (12-14.5)%, RET (17.8-64.9)x109/L, LFR (91.7-99.3)%, IRF (0.7-8.3)%. RIs in the age group "b12" and "12-60" months had no differences in WBC (6.0-13.6)x109/L, EO (0.07-0.88)x109/L, PLT (267-580)x109/L, HGB (111-133)g/L, RBC (4.02-5.30)x1012/L, HCT (32-40)%, MCV (71.5-86.3)fL, MCH (23.9-29.3)pg. RIs in the age group "60-120" and "N120" months had no differences in WBC (3.9-11.5)x109/L, EO (0.02-0.65)x109/L, PLT (175-436)x109/L, RBC (4.09-5.33)x1012/L, MCH (24.9-30.4)pg. In the age group "b12" months RIs for NEUT was (0.6-3.6)x109/L, in children older than 12 months RIs NEUT was (1.1-5.8)x109/L. Absolute count of LYMPH was different in all the age groups: "b12" (3.3-9.0)x109/L, "12-60" (1.6-7.1)x109/L, "60-120" (0.9-5.0)x109/L, "N120" (1.1-3.8)x109/L. Red blood cells parameters differed in two groups: "60-120" -HGB (114-147)g/L, MCV (76.6-89.7)fL, HCT (35-43)% and "N120" -HGB (118-155)g/L, MCV (78.6-92.9)fL, HCT (37-46)%.
CONCLUSIONS
These data will help to implement hemogram parameters in the everyday clinical practice needs. 
Background-aim
Autoantibody measurement is key for the diagnosis of autoimmune diseases. It is essential for these measurements to be reliable and on the longer run standardised. Standardisation can be assisted through the use of an appropriate reference material (RM). A useful RM must fulfil a number of criteria. It must be homogeneous, stable at certain temperatures and preferably over longer periods of time. It must be fit for purpose and commutable, i.e. to behave as any patient sample. The Joint Research Centre of the European Commission has released a RM certified for PR3 ANCA IgG autoantibodies (ERM-DA483/IFCC). Antibodies that are involved in cases of small vessel associated vasculitis. Thus, prior to anything else, commutability of different possible formats for this material were assessed.
Methods
Commutability was assessed in 2 separate studies. During the first one, 18 formats of the candidate RM were tested with eight commercial immunoassays alongside 30 clinical samples. During the second study, 3 of the most promising candidate RMs and dilutions thereof were analysed with another set of 30 clinical samples with three immunoassays so as to select the format that would be best for preparing the CRM. The data derived from these studies were compared in a pairwise manner and Pearson's correlation coefficient for the samples of all pairs was calculated. Additionally, the intermediate precision and repeatability were evaluated.
Results
Commutability can be analysed with different statistical approaches. Through the studies, the formats that led to results not being within the 95% prediction interval of a pairwise analysis were rejected. The inter-and intra-plate variations were below 7% for all assays. Eventually one format was selected for the candidate CRM, it was a plasmapheresis material with high concentration of PR3 ANCA IgG that was converted into serum and freeze-dried.
Conclusions
The results confirmed that there is a large variability in PR3 ANCA IgG testing despite the overall good performance of individual immunoassays. However, through properly designed and performed commutability studies a suitable format for a CRM could be selected. Together with the detailed instruction for use, the CRM produced (ERM-DA483/IFCC) will allow control of the variation in PR3 ANCA IgG measurements. 
Background-aim
In a clinical biochemistry laboratory, there are many determinants responsible for sample rejection, the majority of them falling into the pre-analytical phase of errors. With advances in Laboratory & Clinical Medicine, clinical diagnosis is largely based upon biochemical investigations. Collecting and analyzing data consistently are necessary tasks for assessing quality, monitoring standardized key processes, improving performance and patient safety in clinical laboratories.
With a few comparative studies available, it has been found that the rate of sample rejection is strongly related to quality control and can serve as an effective quality indicator. In this study, we have compared and analyzed data collected from two tertiary care hospitals with a primary focus on ruling out reasons for rejection and identifying specific volatile test groups.
The aim of this study is to establish a cohort relation between the rate of sample rejection and quality indicators with an evidencebased explanation for rejected samples.
Primary objective -Primary objective of this study is to develop a Standard Operating Protocol (SOP) to answer and check all the specific causes of sample rejection & improve Total Test Process (TTP).
Secondary objective -1. Check for novel factors for improving TTP, depending upon the comparative variables & compounding from the two tertiary care hospitals. 2. To validate the SOP and minimizing unintelligible errors and improving the quality of sample/specimen collection.
Methods
This study is based upon retrospective data analysis of all the biochemistry samples received and the total number of samples rejected in 1 year from clinical biochemistry laboratories of two tertiary care hospitals. Both hospitals are from Southern Karnataka region, one being 1800 bed & the other is 850-bed strength. The clinical biochemistry laboratory of the respective hospitals are following NABL (National Accreditation Board for Testing and Calibration Laboratories) guidelines for sample collection & rejection. This descriptive study is based on the analysis of different rejection rate, types of unintelligible approach and level of inappropriateness. Assays and blood samples of clinical chemistry, hormonal assay, hematology, HbA1c, urine chemistry, arterial blood gas (ABG) etc. have been evaluated. We have used predefined criteria for sample rejection to assess the level of appropriateness, which are hemolysis, insufficient volume, clotted, wrong vacutainer, mis-match, venous blood (for ABG) and test raised by mistake.
After calculating the mean rejection rate we compared the data with other national and international laboratories.
Results
The total number of clinical biochemistry laboratory samples from test group A received from 1st January 2016 to 31st December 2016 is 1,62,079 of which 1617 (per year) samples were rejected with annual sample rejection rate is 1% (0.997%). In this study, we have followed the standardized sample rejection criteria, among which hemolysis (50%) is the most common reason and mismatch (0.61%) is the least common reason. Among the inpatient departments, medicine has the highest percentage (31%) and pediatrics has the lowest percentage (0.86%). The total number of clinical biochemistry laboratory samples from test group B received from 1st January 2016 to 31st December 2016 is 3,65,000 of which 3,600 (per year) samples were rejected with an annual sample rejection rate of 1% ( 0.9863%).
After comparing grouped criteria of sample rejection with other laboratories we found that hemolysis, insufficient volume, and clotted sample are common. Beside common criteria, some other causes like the venous sample for arterial blood gas analysis with a rejection rate of 12% are the 2nd most common cause.
Conclusions
We need a median rejection rate to compare rejection rates from various clinical biochemistry laboratories. Variation in rejection rates is dependent upon different criteria adopted by different laboratories. One significant retrospective finding of this study is that the quality of the collected sample is crucial. If the quality of the collected sample or specimen is not clinically good then it initiates a vicious chain reaction, as when the quality of a blood specimen is poor, it cannot be processed by the laboratory, this leads to a rerequest for blood specimen and therefore to an increased turnaround time (TT) for the laboratory, which is positively correlated with the delay in diagnosis and undue increment in the expenses both for the patient and the hospital.
In the era of evidence-based medicine, clinical biochemistry laboratory lies at the core of diagnosis and treatment. Clinical diagnosis pertaining to the services rendered by biochemistry laboratories cannot afford to increase the turn-around time (TT) and compromise on the total test process (TTP).
Further national & international comparative studies involving multiple laboratories should be done to design a manifesto to detect and correct varied determinants of sample rejection. 
Background-aim
Proteins are the most abundant macromolecules of human serum, they provide essential functions to the life. Their dosage is a daily need in human medicine. However, the fractionation of serum proteins is essential for the interpretation of any measured anomaly. This fractionation is possible thanks to electrophoresis.
Electrophoresis of serum proteins is a particularly useful analysis in many pathological situations: to guide a diagnosis, to specify the severity of a disease or to follow the effectiveness of a therapy. It also provides a lot of information on the inflammatory, nutritional, infectious state and in particular allows the screening and monitoring of monoclonal gammopathies.
Several electrophoretic techniques are currently available. The most efficient technique currently used, with an excellent resolving power, is capillary electrophoresis, which tends to replace, more and more, the other traditional methods.
The CPMC (Pierre and Marie Curie Center) Biochemistry Laboratory has acquired an automated capillary electrophoresis system: V8® Helena. International recommendations (ISO 15189) require the validation of any new technique before it can be used routinely. In this context, our aim is to validate capillary electrophoresis on this system.
Methods
This work was made at the CPMC biochemistry laboratory, from January 26 to March 20, 2017.
− To verify the analytical performance of the automated V8 system, we followed the recommendations of the SFBC protocol for Verification / validation of the performance of an analytical method. − epeatability and reproducibility were assessed using control sera of two levels of concentrations 58 and 77g /L. − comparison was made with another capillary electrophoresis system, CAPILLARYS 2® (Sebia) from the biochemistry laboratory of CHU MOHAMED NEDIR of Tizi-Ouzou, Algeria. − 123 sera were analyzed first on Capillarys2 ®, then sent to the CPMC Biochemistry laboratory and kept at + 4°C. The analysis on V8® (Helena) was performed the next morning. − The total proteins of these sera were assayed by the Biuret method on the INDIKO® (ThermoScientific) analyzer . − The evaluation of the agreement between the two analysers was carried out according to the recommendations of the Cofrac by the Bland-Altman diagram and the Passing-Bablok regression line. − The statistical study was carried out by XL-Stat 2014 software.
Results
The coefficients of variation found for the study of the repeatability and reproducibility of the different fractions (albumin, 〈1, 〈2, ®, ©) were all less than 4%.
The comparative study showed that there is a good agreement between the results of the two systems, the differences found by the Bland and Altman diagram were b2.1% for all the protein fractions, the widest difference was that obtained for the Beta fraction (2.1%).
The 
CONCLUSIONS
This study has demonstrated the performance of the Helena V8, attesting that it could advantageously be an appropriate alternative for serum protein separation methods in medical analysis laboratories. 
Background-aim
The new core lab automation at Ghent University Hospital includes an innovative cartridgeless pneumatic tube sample transportation system (Tempus600™) from the emergency department (ED). Samples cover 172 m in 20-25 s and enter the (pre)-analytical automation directly via a bulk loader, significantly reducing prelaboratory TAT. SSTII, a low-vacuum serum tube (6.0 mL) with 30 min clotting time, was previously the preferred tube, however now conflicted with reduced TAT. This study examined suitable successors to SSTII, albeit SSTII quality and user friendliness need to be upheld.
Methods
The 5.0 mL BD Rapid Serum Tube (RST) contains thrombin resulting in 5 min clotting time. An exhaustive literature review showed RST to maintain standard-of-care. Consecutively, RST replaced SSTII at the ED from 13-30/11/17 (n = 818). Evaluation of RST was based on median haemolysis index (MHI) and haemolytic samples incidence (HSI) with samples being haemolytic from a haemolysis index (HI) ε 88. Retrospective comparison was made with SSTII samples 1 year prior (i.e. 13-30/11/16).
Following, 2 Li-heparin plasma tubes (PSTII BD Vacutainer 4.5 mL and Barricor 3.5 mL) were subjected to a prospective, randomized study at the ED (n = 91). First SSTII was drawn from patients admitted to ED who gave informed consent, followed by PSTII and Barricor randomized. Transportation occurred randomized, via either Aerocom™ (cartridge pneumatic tube system) or Tempus600™. LD, K, Na, Cl, AST, ALT, creatinine, glucose, urea, HI and CK were determined.
Results
RST showed an increased MHI (p b 0.001; SSTII = 7; RST = 11) and increased HSI (p b 0.0001; SSTII = 3.7%; RST = 8.0%) compared to SSTII. Next, Bland-Altman and Passing-Bablok analysis of Liheparin tubes showed ample clinically significant differences compared to SSTII, except K as expected. However an unexpected difference for LD was observed for both and PSTII increased HSI in ED-specific setting.
Conclusions
Increased HSI and MHI rendered RST unsuitable. Based on haemolysis incidence, the low vacuum Barricor is the most suitable tube. However, various ED nurses expressed the Barricor slow filling as undesirable. Tempus600™ did not alter chemistry results. 
Background-aim
Determination of IgG subclasses concentration is often used when there is suspicion of antibody deficiencies or IgG4 related disease. Validation of the individual results is often done by comparing the sum of the 4 IgG subclasses with the result obtained from Total IgG assays (IgGt). However, often, discrepancies arise and additional testing becomes necessary. Presently, there is no international reference material for IgG calibration, with each manufacturer adopting a different calibration standard. The objective of this work was to investigate the potential impact of different calibration materials in the correlation between IgG subclasses and IgGt assays.
Methods
Thirty-six serum samples were analyzed with IgG subclasses and total IgG assays from The Binding Site (TBS, Birmingham, UK) in the OPTILITE turbidimeter (TBS), both calibrated against the standard ERM-DA470k, and with total IgG from Siemens Healthcare (SH, Erlangen, Germany) in an AU5800 series (Beckman Coulter, California, US), calibrated against a different standard. Statistical analysis done using Excel and Analyse-it.
Results
The correlation coefficient (r) between the sum of IgG subclasses and IgGt determination was 0.974 for TBS assays and 0.939 for SH assay. The Bland-Altman analysis showed a mean relative difference of 0.4% (95%CI: -2.0% to 2.8%) between the sum of IgG subclasses and IgGt from TBS and of 24.3% (95%CI: 20.9% to 27.6%) when comparing with the IgGt assay from SH.
Conclusions
The analysis shows that, although the correlation between IgG subclasses from TBS and the IgGt assays from both providers is very good (RN0.93), the agreement is clearly superior when the assays are from the same provider, suggesting that the discrepancies frequently observed between both results are likely to be due, mainly, to the different reference materials to which different providers calibrate their assays. 
Background-aim
Natriuretic peptides [B-type natriuretic peptide (BNP) and Nterminal pro-BNP (NT-proBNP)] are useful biomarkers for diagnosis and prognosis of heart failure (HF). Stability of BNP assays must be examined, because there appears to be assay dependence, according to IFCC recommendations. The aim of this study was to evaluate BNP stability in plasma EDTA samples in different handling conditions, assayed with a Lumipulse G BNP assay.
Methods
Blood samples were drawn into blood tubes containing ethylenediaminetetraacetic acid (EDTA), in two groups: group A, including 6 healthy individuals, and group B, including 5 patients admitted to the Internal Medicine Department with HF. After centrifuging immediately, plasma BNP levels were assayed at baseline and then at 4, 12 and 24 hours after collection, stored under room temperature and refrigerated (4°C). BNP levels were measured on a LUMIPULSE G 600II analyser (Fujirebio), based on a chemiluminiscence immunoassay.
A change was considered significant when percent deviation (PD %) from baseline BNP level, defined as 1.65*CVA (analytical variation coefficient) was higher than 4.8% and 4.1% in groups A and B, respectively. Analysis of results was performed according to the criteria proposed by the SEQC-ML.
Results
Baseline BNP levels ranged from 6.1 to 26.3 pg/mL [mean (SD)]: 12.8 pg/mL (7.7)] in group A and from 191.0 to 824.7 pg/mL [mean (SD): 440.6 pg/mL (289.9) ] in group B.
At room temperature, BNP levels decreased progressively in both groups, remaining stable within 12 hours from collection only in group A. PD for samples at room temperature were -1.1% and -4.0% at 4 hours, -4.5% and -13.8% at 12 hours and -8.0% and -14.4% at 24 hours, in groups A and B, respectively.
Similarly, at 4°C, BNP levels also declined progressively, remaining stable for up to 12 hours at physiological levels, but their concentrations at pathological levels only were stable within 4 hours from collection. For samples at 4°C, PD were -0.012% and 1.3% at 4 hours, -3.5% and -5.6% at 12 hours and -7.6% and -6.5% at 24 hours, in groups A and B, respectively.
Conclusions
Plasma BNP is stable for at least 4 hours from blood collection until its measurement, as recommended by the manufacturer. 
Background-aim
Hyponatremia (HP) is the biochemical finding in blood, plasma or serum sodium concentration (Na) b135 mmol/L. It is one of the most common disorders of body fluids but it is also one of the most underdiagnosed. Early detection and treatment are essential to avoid fatal consequences, especially in patients (PA) with moderate and severe HP (Na b130 mmol/L) (sHP). Therefore, the Medicine Laboratory implemented a diagnostic algorithm (DA) applied to clinical laboratory (LAB) and POCT analyzer (POCT) results to help clinicians improve the detection and management of HP.
This DA included a correction of Na due to hyperglycaemia. If HP was not corrected, an automatic comment (AC) in the POCT report was incorporated recommending to send a serum sample to the LAB to measure osmolality (OS). If HP was evidenced in LAB, OS was automatically measured. When serum OS was b275 mOsm/Kg, an AC in the report asked for a urine sample to measure electrolytes and osmolality. If OS was N275 mOsm/Kg, the AC recommended to rule out the presence of osmotically active substances.
The aim of this study is to evaluate the outcome of the DA on the elapsed time between the initial detection of a sHP and the next test request with Na ε130 mmol/L.
Methods
This is an observational and retrospective study that included all PA (adults and children) from the Emergency and Nephrology Departments with Na b130 mmol/L. Na was measured by Indirect potentiometry (P) and in POCT by direct P. An episode of HP was considered as the period of time that began when a PA showed a Na b130 mmol/L and finished when Na ε130 mmol/L. We obtained the results from the laboratory information system during six months, before (665 PA) and after (710 PA) the implementation and were homogeneous. The database was analyzed with SPSS program by the Mann-Whitney U test.
Results
The time for the episode of HP (average ± standard deviation) was:
Before: 22.3 ±22.7hours. After: 19.0 ±23.1hours. This difference was statistically significant (p b0.001).
CONCLUSIONS
The incorporation of this DA by laboratory in clinical practice contributed to decrease the time between the initial HP and the next test request with Na ε130 mmol/L. These actions are relevant to improve the detection, classification and management of PA with HP. 
Background-AIM
The glycosylated hemoglobin (HbA1c) is the reference test for the monitoring of glycemic control of diabetic patients in the long term.
There are different methods for the quantification of HbA1c. The method of determination of the IFCC (International Federation of Clinical Chemistry and Laboratory Medicine) is suitable as a reference method, although it is impracticable for the routine determination of HbA1c. Therefore, the method designated by the DCCT (Diabetes Control and Complications Trial) as a comparator method is ion exchange HPLC, being widely used by the Clinical Biochemistry Laboratories for the determination of HbA1c routinely.
The aim of this study was to evaluate the concordance of the HbA1c measurement obtained in the Variant II Turbo (BIO-RAD) and Tosoh G8 (HORIBA) analyzers.
Methods
We analyzed 110 samples of whole blood-EDTA-K3 in a range of values between 3.8% and 13.9%. The samples were processed in parallel and, to minimize the preanalytical error, the analysis was performed in the two teams following a sequential order: first in the Variant II Turbo analyzer (reference analyzer) and later in the Tosoh G8 analyzer (analyzer in process of assessment).
The statistical analysis for the comparison of methods was carried out by Passing-Bablok regression and the analysis of the differences using Bland-Altman with the statistical program Method Validator®. The cut-point analysis was performed using ROC Curves with the statistical package SPSS 19.0.
Results
The Passing-Bablok and Bland-Altman regressions showed that systematic differences of constant and proportional type were not found between the two methods. The equation of the line obtained when comparing the results between the two analyzers was: Tosoh G8 = 0.000 + 0.956 Variant II Turbo, with a confidence interval of 95%. The results showed a high correlation between both teams (r = 0.956).
Conclusions
The results obtained in the Tosoh G8 analyzer were traceable and comparable to those of the Variant II Turbo analyzer, so it is possible to ensure the transferability of the results between both teams. In addition, the Tosoh G8 analyzer improves the workflow and productivity of the laboratory since the processing time of each sample is less (108 seconds). 
Background-aim
Hypomagnesemia is a condition necessary to be detected in Emergency Department (ED) patients, as it often leads to hypocalcemia that does not resolve until the magnesium deficiency has been corrected. The objective was to show and monitor an intervention to identify ED patients with hypomagnesemia.
Methods
The stat laboratory is an independent laboratory located in the central University Hospital Laboratory in a health district of Alicante, Spain. The laboratory serves a population of 234,403 and processes requests for in-patients and ED patients. A Cross-sectional study was performed on ED patients who had hypocalcemia between July 2016 and December 2018. In a meeting between the laboratory and ED physicians we devised a strategy that consisted that the laboratory information system would automate register serum magnesium (smagnesium) when patient presented hypocalcemia (Albumin-adjusted total calcium N 7,5 mg/dL). We counted the number of detected patients with hypomagnesemia (s-magnesium b1,8 mg/dL) and calculated the cost in reagent of each identified case.
Results
S-magnesium was automatically added to 323 samples that presented low albumin-adjusted total calcium values, with 161 hypomagnesemia results. 119 identified patients with hypomagnesemia in a 2,5 year period. Each case represented a cost of 0,84 euros.
Conclusions
The intervention to identify patients with hypomagnesemia seems cost-effective. Moreover, patients have an excellent prognosis since once the deficiency is detected and corrected the symptoms are reversible with treatment. 
Background-aim
Year after year, manufacturers offer us new analyzers postulating that the new model is better than the previous one. The laboratory, in turn, needs to make the right choice between the technics and analyzers or have objective arguments in favor a new generation. Frequently, a focus is on reducing the cost of analytics, but this should not be considered in isolation. Pre-analytical processes in production -tube philosophy and probe sorting -also can affect costs.
Methods
Methodology of the Total Cost of Ownership (TCO) as a practical study was carried out in the core laboratories and enabled us to make an assumption of the real cost of pre-analytics, real throughput of analyzers and to structure direct and hidden costs.
In this study, four independent laboratories in France ran 1000 requests of clinical chemistry (CC) and immunoassay (IC) test panels of 32 analytes (among them 400 requests CC, 350 -IC, 200 -mixed (CC+IC) and 50 urgent requests) using standardized protocols on different analytic platforms from Abbott (ARCHITECT c8000, ARCHI-TECT i4000, ARCHITECT i1000), Beckman Coulter (AU2700, AU5800, DxI 800), Roche (COBAS c701, COBAS c502, COBAS e602) working in different combinations with different pre-analytical platforms (MPL track, Inpeco track, standalone AutoMate 2500). Key operational efficiency areas that contribute to TCO were measured: sorting speed, maintenance time (separate human and machine time), processing time (total (TAT), per tube, per test) and utility consumption.
Results
Obtained results demonstrate that not only analytic platforms but pre-analytical platforms also affect the processing speed and the same analyzers demonstrate diverse efficiency when they are built into the track compared to working with standalone sorters. Different kinds of tube use and priority of primary tube sequence (CC, IC) also impact TAT and costs and should be determined for each laboratory individually.
Conclusions
Methodology of the TCO enables a detailed assessment of costs to be carried out and a new technological solution to meet the needs of laboratories can be chosen. This makes it possible to use evidencebased real-life management tools for calculating and controlling the costs while still ensuring high-quality test results. 
Background-aim
For optimization of laboratory work flow it is necessary to reduce the time-consuming manual task of aliquotation. To achieve this, the stability of plasma proteins when stored in serum gel separator tubes (SSTs) needs to be evaluated and compared to aliquots tubes as currently used in the laboratory. The aim of this preliminary study was to determine plasma protein stability in SSTs compared to aliquots tubes.
Methods
Nephelometric quantification of plasma proteins in seven consecutive samples was performed on BN ProSpec System simultaneously in SSTs and aliquots tubes after 3, 7 and 10 days of storage at 2-8°C. Seven analytes were measured on each sample, i.e. albumin, haptoglobin, orosomucoid, alpha-1-antitrypsin, immunoglobulin G (IgG), immunoglobulin A (IgA) and immunoglobulin M (IgM). Prior to aliquotation and analysis SSTs were allowed to clot for 30 min at a room temperature of 18-25°C and subsequently centrifuged at 2000g for 10 min. To evaluate the results, laboratory calculated coefficient of variation (CV) was compared to CV obtained from quantification during storage for each sample's SST and aliquots tube.
Results
All but one analyte remained stable during storage in both SSTs and aliquots tubes. Four of the seven samples had a satisfactory correlation for all analytes when comparing laboratory calculated CVs with CVs obtained from quantification during storage. That is, CVs obtained from stored tubes was lower than expected demonstrating that plasma proteins are stable in both SSTs and aliquots tubes. In the remaining three samples a satisfactory correlation for all analytes with the exception of IgM was found. IgM presented a higher CV than expected after storage for both SSTs and aliquots tubes with no preference for either of the two tube types. This may be due to increase in IgM concentration during storage and corresponding trend was also observed for the other analytes but did not affect CV to the same extent.
Conclusions
This preliminary study shows that there is no difference in plasma protein stability comparing SSTs and aliquots tubes for up to 10 days of storage. The result thus suggests that storage of samples in SSTs is comparable to that in aliquots tubes. However, to validate these findings a more comprehensive study with larger sample size would be necessary. 
Background-aim
Potassium ethylenediaminetetraacetic acid (kEDTA) is a widely used blood anticoagulant in laboratory sample tubes. EDTA contamination of clinical chemistry serum samples may result in spurious hyperkalaemia and hypocalcaemia. If unrecognised, this could adversely affect patient care. Strategies for identifying serum kEDTA contamination are typically based upon a combination of raised potassium and low alkaline phosphatase and calcium results,but this approach is subjective. We performed a validation of an assay for EDTA on an Abbott Architect c16000 analyser with the aim of introducing it into routine use.
Methods
Intra-/Inter-batch imprecision, linearity, recovery, interference and carryover were assessed. Serum was spiked kEDTA plasma to mimic sample contamination and the effect on EDTA, potassium, calcium, magnesium, ALP and zinc concentration was established.
Results
The assay displayed acceptable imprecision, recovery and linearity. No significant carryover was detected but the assay was subject to positive interference from haemolysis. EDTA contamination was detectable when serum was contaminated with 1% (v:v) kEDTA plasma. A change in serum potassium of 0.54 mmol/L (11.9% was observed) at a measured EDTA concentration of 0.19 mmol/L; equivalent to a contamination of 3. 2% (v:v) . At the same level of contamination, reductions in measured levels of calcium (4.7%), zinc (-22.2%) and ALP (4.7%) were observed; no change was observed for magnesium.
Conclusions
The EDTA assay displayed acceptable performance. Even small levels of kEDTA contamination were detectable. Routine measurement of serum EDTA concentrations has the potential to identify low levels of contamination which may not be detected using more subjective measures. 
Background-aim
Urinalysis (UA) is the third most commonly used laboratory diagnostic test, with 70% of UA errors occurring in the preanalytic phase.
Diagnosis made from the UA should be based on standardized procedures for collection, transport and analysis.
The presence of proteinuria may be a sign of renal damage. According to the European Urinalysis Standards published in 2000, under the auspices of the European Federation of Laboratory Medicine, urine samples should be collected free of internal and external contaminants, so sexual intercourses should be avoided at least one day because the presence of semen interferes positively with proteinuria. Several published articles corroborate this principle.
Objectives. Determine if the presence of semen in urine lead to identification of proteinuria in urine test strips (TS) used in the urinalysis.
Methods
Through the observation of urinary sediments in an automated equipment, a total of 50 samples were selected due to the presence of spermatozoa.
At the same time, the proteinuria values of each sample, obtained through the use of TS were evaluated. Once it could not be excluded that the presence of proteinuria could be due to the underlying pathology, only the relationship between the presence of spermatozoa in urine and the absence of proteinuria was studied.
Statistical evaluation was performed using the IBM® SPSS® Statistics V24 program.
Results
Of the 50 samples studied, 43 samples were male urine (mean age 52 ± 17 years) and 7 female (mean age 42 ± 9 years).
No proteinuria was detected in 74% of the samples. This was not observed in 72.1% of the samples of men nor in 85.7% of women.
Conclusions
It can be concluded that the simple presence of semen in urine is not a determining factor for the identification of proteins in the urine, with less influence in women than in men.
Additional studies should be carried out to determine the concentration at which the presence of semen determines the erroneous identification of proteinuria. 
Background-aim
Since up to 70% of errors in laboratory testing occur in the preanalytical phase, to improve patient safety it is necessary to carefully manage the related risk, as required by accreditation: the assessment discloses criticalities and helps in decisions. We aim to provide methodological elements for an effective management, by objectively measuring the risk connected to the phases handled by man compared to those automated. Our clinical laboratory belongs to the University Hospital of Siena and offers diagnostics both to inpatients and to outpatients. Since the management of these two flows has different degree of automation, it allows to evaluate the risk associated with different kind of preanalytics. To this aim we applied the proactive methodology FMECA (Failure Mode Effects and Criticality Analysis).
Methods
Our multidisciplinary team divided the 3 phases (prepreanalytical, preanalytical outside and within the lab) in 11 subphases (formulation of clinical question, test selection, prescription; acceptance, preparation, identification, labelling, collection, conservation, transportation; preparation for analysis) and defined 18 main activities, recognising the ones already automated from those still human handled. For each we identified failure modes and effects on clinical outcome. According to literature data and our quality indicators, we assigned scores to severity, probability and detectability using ten-point scales. We calculated the risk indexes (RI) that varied from 32 to 243.
Results
The sum of RI obtained from human activities resulted much higher than the one produced by automation. The most critical steps (RIN150) were: manual acceptance of test orders, patient identification, tube labelling and sample collection. Our results suggest to introduce automated phlebotomy tray preparation systems, already available for outpatients, in wards.
Conclusions
Although automation has a fundamental role, each organization is different about workloads and competencies, so the most suitable management must be tailor-made. Our methodology represents a useful tool to predict the risk related to scenarios with more or less automation and to choose the best balance according to the needs. The cyclic repetition of this analysis allows to measure the effectiveness of the action adopted. 
Background-aim
The patient-centered evaluation of pre-analytical errors through risk management based on the implementation of harmonized quality indicators (QIs) is an important tool used for pre-analytical quality improvement and patient safety. The aim of this study was to assess the impact of phlebotomy educational activities based on the ISO 15189 requirements and the National recommendations for venous and capillary blood sampling using the Failure Mode and Effects Analysis (FMEA). 
Methods
From January to
Background-aim
For some steroid hormones, we could observe interferences in the peaks measured by liquid chromatography tandem mass-spectrometry (LC-MS/MS). Therefore, the influence of gel or non-gel separators should be evaluated to assess the stability of steroid hormones. The aim of this study was to evaluated the performance of the BD Vacutainer® Serum (BD Serum) tube, the BD Vacutainer® SST™ II Advance (BD SST II Advance™) tube with gel separator, the BD Vacutainer® Heparin (BD LiHep) tube and the BD Vacutainer® Barricor™ (BD Barricor™) tube, a lithium-heparin plasma tube with mechanical non-gel separator, for the stability of 15 steroid hormones over different time intervals.
Methods
After informed consent, 10 healthy individuals were included in the study. From each subject, 4 blood sample tubes were drawn: BD Serum, BD SST II Advance™, BD LiHep and BD Barricor™. Concentration measurements of 15 steroids were performed by LC-MS/MS using the Steroids MassChrom kit with QTRAP6500. Primary samples (T0) were centrifuged and aliquots were taken and frozen for further analysis. The primary tubes were stored at 2-8°C. After 4 days (T4), 7 days (T7) and 15 days (T15), aliquots were taken from the primary tubes and frozen for further analysis. The data were analyzed to compare the results between the tube at T0 and to compare the results from the same tube at different time points to evaluate within-tube steroid stability, using an Analysis of Variance (ANOVA), the Acceptable Change limit (ACL), that takes the analytical coefficient of variation (CV) in consideration and the Total Change Limit (TCL), that takes both the analytical and the biological CV in consideration.
Results
At T0, statistical differences were observed between the tubes for 8 steroids. However, from the ACL and TCL point of view, the between-tube comparison did not show any difference at initial time. The within-tube stability showed statistical differences for 7 steroids after 15 days, 2 steroids after 7 days and 3 steroids after 4 days.
The ability to tolerate lactose is determined by intestinal activity of the lactase enzyme. There are several DNA variants of the lactase gene (MCM6) rending the person tolerant to lactose. We perform a test for the single-nucleotide polymorphism (SNP) C/T 13910 DNA variant, called Lactose intolerance (LI) test, which is the most common SNP in the Northern European countries. Any repetition of this test is considered inappropriate.
We investigated the effect of blocking repetition of this test on the number of requests from hospitals and compared with unblocked requests from general practitioners (GPs) in the Region of Southern Denmark.
Methods
Blocking, in which repeated requests for the LI test on the same patient were not allowed for "life-time", was introduced in the hospital ordering system December 1st 2015. The observation periods were 2,5 years before and after blocking, respectively.
Results
In hospital settings, LI test requests were 10,138 and 7,331 before and after intervention, respectively. Repeats decreased from 416 (4.1 %) before blocking to 33 (0.5%) after blocking. The number of LI tests requested by GPs was 14,887 before and 18,281 after the intervention, while the number of tests repeated was 579 (3.9%) and 643 (3.5%) before and after intervention, respectively.
Conclusions
Blocking of LI tests is an effective way of reducing inappropriate retesting in hospitals. But the decrease in LI tests in the hospitals cannot only be explained by the blocking.
The number of repeated LI tests ordered by GPs was comparable in the two periods evaluated. Furthermore, the number of tests requested by GPs increased during the 2,5 years.
We hypothesize that the considerable increase in the number of LI tests requested by GPs indirectly caused the decreasing number of requests in hospitals as, once the patient´s LI status has been tested, hospital wards are not allowed to repeat the test. Furthermore, the blocking of requests from GPs also would expect to result in an approximately 3.5% reduction of requests, which corresponded to an annual reduction of ca. 250 LI requests. 
Background-aim
Recently EFLM published recommendations for management of hemolyzed samples (HS) in an attempt to harmonization. There is a strong recommendation for implementation of automated algorithm-based decision rules with the measurement of serum index.
Nevertheless, the document did not mention the difficulty of distinguish between in vivo hemolysis (IVH) and spurious hemolysis. A differentiation has to be carried out in every HS. Despite IVH is infrequent, the annulation of interfered parameters could cause delays in the patient diagnostic.
In IVH, levels of bilirubin increase rapidly. This particularity has been used to implement our decision algorithm in HS. Rarely IVH courses with normal levels of bilirubin (TB). Only in these cases, interfered parameters are automatically annulated.
Methods
When the sample is not hemolyzed, the results are released. When the sample is mildly hemolyzed (hemoglobin from 10 to 25 mg/dL) a comment is added warning about the possibly of interfered test. When hemoglobin exceeds 25 mg/dL, the algorithm also takes into account the icteric index (II). If II is normal (II=1) the interfered parameters are suppressed and a specific comment is added. When the II is abnormal (IIε2) the Total Bilirubin (TB) is implemented. If the TB is normal, the interfered parameters are suppressed. But when the TB is altered (TBε1 mg/dL) the interfered parameters are shown with a comment to be valued together with clinical data of the patient by the clinician.
Results
During the year 2018, 196.095 samples were analyzed, 12.004 (6%) presented hemolysis. 11.336 (95%) had normal II therefore interfered parameters were suppressed. Only 593 (5%) of the HS had altered TB and the interfered results were shown.
Conclusions
Most of HS received in laboratory are due to spurious hemolysis. Only in a few percentage, the interfered parameters will be released to be assessed together with patient's clinic because laboratory is not able to distinguish the hemolysis type.
Despite IVH is an infrequent disease, the cancellation of interfered parameters could cause delays in the adequate patient management. The icteric status can be easily incorporated in the algorithm decision rules of hemolyzed samples improving patient safety. 
Background-aim
The VITROS® XT 7600 Integrated System (VITROS XT 7600) from Ortho Clinical Diagnostics can perform general chemistry and immunoassays by combining its MicroSlide, MicroTip, and MicroWell (with enhanced chemiluminescence) technologies into one instrument platform. We conducted an evaluation to access the impact on productivity at our institution, of the VITROS XT 7600 Integrated System for use with the new VITROS XT Chemistry Products Slides. A series of new VITROS XT Chemistry Products Slides (XT MicroSlides) with dual test capability have been developed. They are intended to reduce sample size and enhance operational efficiency while maintaining analytical performance versus the conventional single slide test. The six new XT MicroSlides products are the following: UREA-CREA Slides, ALTV-AST Slides, TRIG-CHOL Slides, ALB-TP Slides, GLU-Ca Slides, and TBIL-ALKP Slides. These new slide products are unique in that they allow testing for two different analytes to be performed simultaneously on a single slide in the clinical chemistry laboratory on the VITROS XT 7600. This study examined both the workflow improvements when adding XT MicroSlides to current workflow and the peak throughput impact to the addition of incremental XT MicroSlides to the workflow.
Methods
Peak throughput was assessed on the VITROS XT 7600 using the following four XT MicroSlide assays: UREA-CREA Slides; ALB-TP Slides; TRIG-CHOL Slides and TBIL-ALKP Slides versus eight corresponding single slide test assays: UREA Slides; CREA Slides; ALB Slides; TP Slides; TRIG Slides; CHOL Slides; ALKP Slides; and TBIL Slides. The XT MicroSlides with dual test capability were chosen through their high correlation to the sample workflow, modelled using archived run data, and obtained through Ortho's secure, real time communications eConnectivity database. The Vitros XT 7600 executed a workflow test design with protocols containing MicroSlides, MicroWells, and MicroTips combined and with MicroSlides only.
Results
The peak throughput achieved, was greatest when four of the XT MicroSlides products were studied; resulting in maximum throughputs of 720 TPH with four XT MicroSlides products and 606 TPH with single slide test examining the throughput of MicroSlides only. The maximum throughputs of 731 TPH with four XT MicroSlides products and 617 TPH with single slide test examining the throughput of MicroSlides, MicroWells, and MicroTips combined. A series of protocols tested the maximum throughput using four, three, two, and one XT MicroSlides products versus single slide test products. *For presentation and demonstration purposes only.
Conclusions
In addition, the impact of XT MicroSlides to workflow is reduction in FTE time to manage the following daily, weekly, monthly tasks: incoming consumables inspection/unpacking/storage, hands-on time loading/unloading cartridges, and generation/disposal of solid waste.
VITROS XT Platforms are currently under development and are not available to the public or for sale until approved under the requirements of the DIRECTIVE 98/79/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 27 October 1998 on in vitro diagnostic medical devices and the respective regulatory requirements of the target market 
Background-aim
In laboratory medicine, preanalytics are less standardized than analytics, but the validity of generated data depends on both phases. Variations in blood withdrawal conditions are frequently evident in clinical settings and have been suggested to impact measurements of erythrocyte lysis parameters, such as potassium, free hemoglobin, and lactate dehydrogenase (LDH). LDH activity is routinely determined, e.g. for monitoring malignant diseases. Here we performed an integrative analysis of parameters affected by hemolysis in different matrices under defined preanalytical conditions, including different vacuum blood collection tubes (serum, SE; heparin plasma, HP) and their filling volumes.
Methods
From n=30 healthy volunteers venous blood was withdrawn. Blood tubes were either filled (90-100%) or underfilled (40-50%). Each tube was subjected to analyses of electrolytes (sodium, potassium, chloride), enzymes (LDH, creatine kinase (CK)) as well as quality indices (hemolysis, icterus, lipemia). Further, the blood filling velocity was quantified. Parameters of hemolysis and plasma yield were determined and additionally analyzed retrospectively in nN74.000 in-house patients.
Results
Concerning different matrices (SE vs. HP), both hemolysis index (-11.7%) and potassium concentrations (-7.3%) were expectedly reduced in anticoagulated HP. LDH activity was higher in HP compared to SE (+10.3%), contradicting hemolysis index and potassium. Analyzing the impact of underfilling, the analytes sodium, chloride, and CK remained largely unchanged. However, underfilled tubes were characterized by higher LDH (SE: +21.6%; HP: +29.5%), hemolysis index (SE: +216.1%; HP: +191.7%) and potassium (SE: +4.3%; HP: +5.5%). As one potential underlying mechanism, we determined tube filling velocity, which was~3-fold higher in the first half compared to the second half in both HP and SE. Importantly, in volunteers plasma yield inversely correlated with LDH activity, which was confirmed in our retrospective patient cohort
Conclusions
It is relevant to distinguish between SE and HP collection tubes when using LDH as a risk stratification parameter, since HP produces higher levels. Underfilling of blood tubes leads to elevations in LDH activities, which should be considered in clinically implausible elevated LDH levels. 
Background-Aim
To know the recommendations for the patient preparation for laboratory tests in Primary Care.
Methods
Spain is divided in Health Departments (HDs) composed of several Primary Care Centers (PCCs) and a laboratory attending every HD inhabitant. A cross-sectional REDCONLAB study was designed and a call for data posted by Email. Spanish laboratories were invited to fill out a ten questions questionnaire about fasting recommendations, duration, if customized according to the requested tests, water, other drinks and alcohol ingestion, last meal before fasting and exercise. Also if availability of computerized order entry (CPOE) to automatically print the recommendations in PCCs and if customized, according to the requested tests. An 11th question presented some recommendations, requesting their agreement.
Results 68 laboratories fulfilled the survey. In 46 (68%) HDs fasting was always recommended, 15 just when tests requiring fasting, and in 2 always recommended except when only CBC or CBC plus coagulation tests. In 41 of the 46 laboratories always recommending fasting, was to simplify/unify criteria; In 5 because no CPOE availability.
24 (35%) always recommended a 12-hours fasting; 14, 10-hours, and 18 12 or 10-hours depending weather lipid tests were requested or not. 12 did not specified the duration of fasting, or less than 10 hours.
In 48 (70%) water intake was allowed without restrictions during the fasting period and in 9 to a maximum of ½ liter. In 2, water intake was not allowed and in 9 no recommendations. In 61 (90%), other liquids were not recommended. In 41 was alcohol ingestion specifically not allowed and in 15 no recommendations.
In 45 (66%) a light meal was recommended before fasting. 41 (60%) HDs had specific guidelines regarding non-strenuous exercise in the 3 days prior to analysis, and in 16 were not mentioned.
In 39 (57%), CPOE offered the possibility of printing the recommendations automatically in the PCC that were automatically customized, according to the requested tests. 49 (72%) laboratories agreed with the proposed recommendations.
Conclusions
There was a high variability in Primary Care Patient recommendations before the laboratory tests in Spain, and some do not follow international guidelines. There is a need to reach an agreement. 
Methods
Eighteen surveys distributed between May 2010 and October 2018 were included. PT samples consisted of drug-free, single-donor urine supplemented with specific drugs. A total of 54 challenges (6 per year) were included in the study period. Participants' results were assessed against the reference laboratory, and discordant findings (DF) were investigated by the participant laboratory using a standardized report.
Results
The PT program has expanded to 17 drugs or drug classes for assessment, and enrolled 177 participant laboratories within Canada. The number of positive drugs per challenge ranged from 1-4, and a total of 111 intended positive drug results were distributed during the study period. The error types for 637 discordant findings included analytical method (46.6%), clerical (27.9%), technical (7.7%), equipment (0.9%), and the remainder were unexplained (16.8%). The mean number of DF per positive drug result was 5.9 DF/ Pos. The most frequently misreported results even after normalizing for the number of positive challenges were methamphetamine (17.8 DF/Pos), methadone (7.9 DF/Pos), amphetamine (6.7 DF/Pos), and barbiturates (5.9 DF/Pos). Among the most frequent root causes, method sensitivity and specificity were cited in 14.8% and 13.7% of investigations, respectively. For clerical and interpretation errors, the most frequent were noted for methamphetamine (19.8%), methadone metabolite (EDDP, 14.2%), and amphetamine (12.2%).
Conclusions
The errors identified within PT surveys occurred throughout the testing process with potential impact on patient reports. Although immunoassay drug screen results are considered preliminary or presumptive, their limitations are not necessarily apparent to end users. 
Background-aim
In 2015, our laboratory was alerted by the Physiology department about abnormalities in creatinine clearance values (CrCl), some of which lower than measured GFR ( mGFR, obtained from renal clearance of 51Cr EDTA) which is physiologically impossible. Due to tubular secretion of creatinine, CrCl overestimates mGFR by approximately 20-30%, whereas in the absence of tubular reabsorption or metabolism, CrCl cannot be lower than mGFR. An underestimation of urinary creatinine concentration (UCRE) was therefore suspected, especially in the lower range. Methods UCRE were measured by Dimension Vista Jaffe Creatinine method (CRE2 Siemens Healthcare Diagnostics). Linearity performance and comparison of UCRE measured by urine and plasma mode (reference concentration) were performed.
Results
The test was not linear below 2mM. The bias was inversely related to UCRE (-4.2± 3.4, -9.5± 2.3, 19.6± 4.9 and -25 .9± 8.6 %, respectively for UCRE 2-4, 1.5-2, 1-1.5 and b1mM). The linear relation between UCREb2mM and reference concentration was further used to correct UCRE (corrected UCRE =0.855UCRE+0.435, R 2 = 0,9764). Our laboratory alerted Siemens and the ANSM (Agence nationale de sécurité du medicament et des produits de santé) providing individual patient reports to support the clinical relevance. The bias of CrCl compared to mGFR was studied in 8000 samples between 2015-2018. For UCREb2 mM, there was a linear relation between UCRE and the bias, some CrCl values being lower than mGFR. The correction of UCRE restored the physiologically expected overestimation of mGFR by CrCl. Siemens acknowledged the negative bias at low concentrations of the analytical domain in urine (29 June 2016 Security letter) and that the limit of quantification (0.442 mM) could not be reached. However, the cause was not identified and no solution was provided.
Conclusions
The reported bias potentially leads to a misdiagnosis, since urine creatinine concentration is commonly used to normalize biological parameters for urine concentration. This would for instance impact Albumin-to-Creatinine Ratio (ACR), recommended for risk classification of patients with chronic kidney disease, metanephrines for the diagnosis of pheochromocytoma, bone turnover markers, and many other biomarkers. 
Background-aim
The available scientific evidence supports the use of procalcitonin (PCT) measurement in serum for antibiotic stewardship in septic patients hospitalized in intensive care unit (ICU). PCT should be tested daily until its concentrations decrease by ε80% from the peak value or to absolute values δ0.5 ⎧g/L, at which time both antibiotic therapy and PCT monitoring should be stopped. In our hospital, PCT can be ordered without restrictions by ICU clinicians, who should use the test according to the algorithms described above. However, we noticed a tendency to continue PCT monitoring for most patients well past the '80% decrease from peak value' threshold. To avoid this drawback, we decided to introduce a comment in the PCT report to alert clinicians when the 80% decrease was reached, with the hope of improving request appropriateness.
Methods
Since October 2017, a comment indicating "a decrease ε80% from peak value" was added, whenever relevant, to PCT reports of ICU patients as a clinical validation rule. The number of PCT requests was audited from January to September 2018 (P2) and compared with the same period of 2017 (P1), before the rule implementation.
Results
1103
PCT determinations for 181 ICU patients (mean, 6.1 tests per patient; range 1-60) and 991 PCT determinations for 185 patients (mean, 5.4 tests per patient; range 1-38) were ordered during P1 and P2, respectively. During P2, 258 comments were added to PCT reports of 47 patients (mean, 5.5 comments per patient; range 1-25). This resulted in a 10% decrease in total PCT requests and an average reduction of 0.7 in requests per patient. This corresponded to a yearly saving of~6,000 €.
Conclusions
The post-analytical phase is the most overlooked phase of the total examination process. However, its proper management is crucial for patient safety and clinical governance of laboratory tasks, including appropriate test utilization. We showed that adding a standard comment to the PCT report for highlighting the clinical information given by the biomarker behaviour in ICU patients undergoing antibiotics can increase the appropriateness for this critical, expensive and often misused test. 
Background-aim
Serum is the sample type mostly validated by in-vitro diagnostic companies. However, many patients have conditions that can affect the coagulation process: thrombocytosis, lymphocytosis, anticoagulant therapy, etc. Samples also come from clinics outside the hospital and sometimes the time needed for blood coagulation in serum tubes is not respected, leading to microfibrin problems.
In our efforts to LEAN the total laboratory automation process, we found that the Beckman-Coulter AU5800 analyzers flagged 867 sample blood clotting errors in 1 month, representing an average of 28 errors/day. Resolving each sample blood clot error takes more than 15 min of manual handling by the technologists (recuperating the problematic sample, re-run in front loading mode, verification of analysis completion, etc.). Sample blood clotting errors came mainly from intensive care (20.9%), coronary unit (13.3%), and emergency department (9.2%). Median TAT for potassium on samples with blood clotting errors were 72 minutes, compared to 32 minutes for nonproblematic samples.
Methods
To improve the quality of the samples in our lab, and to lower turnaround times, we decided to use lithium heparin plasma samples collected in BD Barricor™ tubes. These tubes have a mechanical barrier rather than gel to separate plasma from cells. However, before implementing these new tubes, we had to validate an alternative centrifugation time on our Beckman-Coulter centrifuges (5 min at 1912 x g vs the recommended 3 min at 4000 x g). Since plasma was not validated in our Beckman assays, we also compared results obtained for 65 routine chemistry and immunochemistry analyses in Barricor™ tubes in comparison to serum separator tubes for samples from 119 healthy volunteers. Data were analyzed using weighed Deming regression analysis and comparison acceptability was based in mean bias (clinical acceptance limits) and correlation coefficient (r ε 0.975).
Results
The use of Barricor™ tubes showed clinically acceptable equivalence to serum tubes for the studied analytes, and the alternate centrifugation speed did not significantly affect the results.
clinical chemistry tests. Laboratory specialists should now take responsibility for realizing standardized post-analysis.
Methods
Embedded in the Calibration 2.000 program, which initially focused on analytical test standardization, the NUMBER (Dutch UniforM Decision Limits and Reference intervals) project was initiated in the Netherlands for standardization of the post-analytical phase. The NUMBER steering group, together with 16 laboratories, used a big data approach of existing primary care data to deduce reference intervals (RI). The quality of the data used in the big data approach was judged in the SKML MUSE scoring system. Five workshops were organized to reach consensus.
Results
During three workshops agreement was obtained for the RI of 18 standardized clinical chemistry parameters. In the fourth workshop, essential factors were appointed for a successful implementation of these RI. Setting up a website with background information and education was an important outcome. In the fifth workshop an action plan was established and infographics for different users of laboratory results (patient, healthcare specialist, laboratory specialist) were developed.
Besides implementation of the standardized RI, embedding the reference calculations in the Dutch EQAS SKML is essential to accomplish a sustainable infrastructure and database for future data acquisition, both for expansion with new well standardized analytes and for periodic retesting of the established RI in accordance with ISO15189 requirements.
Conclusions
The establishment and implementation of standardized RI based on a big data approach is enabled in the Netherlands, due to a type 1 accuracy-based external quality assessment scheme for general chemistry and fruitful collaborations with quality-minded laboratory specialists. 
Background-aim
The necessity of biobanking is growing more and more nowadays for clinical research. Since most of the researches with biobanking specimen are for later use, the stability of specimen is the most important factor for maintaining quality of research and biobanking. However, there are few researches on the stability of biobanking specimens, particularly long term stability. This study performs the evaluation of the short term and long term stability of common clinical chemistry tests for biobanking specimen.
Methods
Blood specimens are drawn from healthy volunteers. For short term evaluations, specimens are stored at four different temperatures (20, 4, -20 , and -70 degree of Celsius), and analytes are measured at the time of basal, 2, 6, 24, 48, 72 hours and 1 week for 28 kinds of analytes including calcium, phosphorus, glucose, urea nitrogen, uric acid, cholesterol, total protein, albumin, total bilirubin, alkaline phosphatase, AST, ALT, gamma GT, creatinine, sodium, potassium, chloride, total carbonates, iron, total iron binding capacity, triglycerides, HDL, LDL, Immunoglobulin G, A, M, Complement 3 and 4. For long term evaluations, specimens are stored at 2 different temperatures (-20 and -70 degree of Celsius), and analytes are measured at the time of 1, 3, 6 months, 1 and 2 years intervals for same analytes as short term evaluations. Percent differences from basal level for each analyte are evaluated.
Results
For short term evaluation, percent changes of total bilirubin, total carbonates, Complement 3 and 4 show greater than 10 % from basal levels mainly at 20 degree of Celsius. However, for long term evaluations, percent changes of total bilirubin, alkaline phosphatase, AST, ALT, total carbonates, HDL, LDL, Complement 3 and 4 show greater than 10 % starting from 6 months storage mainly at -20 degree of Celsius.
Conclusions
From this study, we can predict how biobanking specimens can be used in clinical researches. Furthermore, alkaline phosphatase, AST, and ALT can be suggested as easily available biomarkers for evaluation of the stability of biobanking specimen. 
Background-aim
Globally, clinical laboratories are producing, communicating, and exchanging millions of laboratory examination results to multiple parties every day. For quantative values, measurement units are required to make numerical values comparable and meaningful. However, a unit may have several expressions, e.g. "mmol/L=μmol/ mL=nmol/μL=pmol/nL". A non-systematic use of several expressions of measurement units may create errors in the vast communication between multiple health care providers and become a risk to patient safety. The Committee of Nomenclature for Properties and Units (C-NPU), a collaboration between International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) and International Union for Pure and Applied Chemistry (IUPAC), recommends using an unambiguous terminology of measurement units, for daily patient care and scientific publications.
Methods
In corporation with international scientific organisations, C-NPU has discussed measurement units and other metrological issues in laboratory terminology for more than 50 years.
Results
C-NPU developed, published, and recommended principles and rules on measurement units.
Examples of some of the principles for SI unit:
1. Base SI units have unambiguous international definitions and should be used 2. Unit of a given magnitude should have only one expression. 3. One SI prefix per unit 4. SI prefix only belongs to the numerator Consequently, "millimoles per litre" shall only be expressed as "mmol/L".
Examples of definitions of some of non-SI units: 
Background-aim
In recent years, BD Barricor™ lithium-heparin plasma tube with a mechanical separator was introduced to improve laboratory workflow and to provide a fast and high-quality plasma sample. We aimed to compare results and stability of thyroid hormones, free T3, free T4, and TSH in the BD Barricor™ lithium-heparin plasma tube, versus BD Rapid Serum Tube, routinely used in the Osijek Clinical Hospital Center laboratory for thyroid hormones analysis.
Methods
Venous blood samples were collected from 43 hospital patients by venipuncture in RST tubes and additionally in Barricor LH (lithium-heparin) tubes. Directly after venipuncture, tubes were carefuly inverted and centrifuged according to manufacturer instructions. Thyroid hormones, free T3, free T4, and TSH were measured by chemiluminescent microparticle immunoassay by Alinity analyzer (Abbott Laboratories, Lake Forest, USA). Venous blood samples collected in the RST tubes were centrifuged within thirty minutes of sampling, for ten minutes at 1300 g. This was followed by the serum separation from the cells, which was used to measure the concentration of selected analytes. Samples collected by venipuncture in Barricor LH tubes were also centrifuged within thirty minutes of sampling, for three minutes at 4000 g.The resulting plasma was also used to measure the concentration of selected analytes. First, we compared results of all three analytes from RST tubes with Barricor™ tubes using Passing-Bablok and Bland-Altman analyses followed by calculating the difference of analytes concentration beetween baseline and a 24h time interval in tubes stored at +4°C.
Results
The results of the test tube comparison in the initial (baseline) time (0) showed a statistically significant difference for a pair of values when determining TSH. Results for TSH obtained using a RST and Barricor tubes were 1,250 (0,580 -2,534) mIU/L and 1,310 (0,605 -2,606) mIU/L (p = 0,002), respectively. Passing-Bablok regression analysis of measured values showed that for TSH and free T3 there is a proportional difference in serum and plasma while Bland-Altman analysis showed an acceptable concordance for all measured analytes. Serum and plasma samples were tested for the analytes stability after a 24 hour tubes storage at 2-8°C and although plasma and serum free T3 and free T4 levels showed statistically significant difference between those two measurements all mean differences were within the range of clinically acceptable deviations for all tested analytes.
Conclusions
Using Barricor tubes improves laboratory workflow and efficiency and also provides a prompt centrifugation and a high-quality plasma sample. Additionaliy, all analyses can be performed within 24h of specimen collection. 
Background-aim
How to manage altered results in HS is a matter of debate and it is even more problematic in infants. In our infant-maternity setting, we apply an approach for reporting interfered test results from plasma HS that provides the result itself, the degree of hemolysis expressed in free hemoglobin (fHb) concentration and a warning recommending sample recollection, if possible. We investigated the impact of this approach on phlebotomy quality and physicians' decision-making process.
Methods
We measured fHb on Beckman AU680 scoring results into 5 intervals of hemolytic index (HI), where HI1 is fHb 0.5-1 g/L and HI5 is fHb N5 g/L. We estimated the total number of HS, the most interfered analytes, the most frequently repeated tests, the clinical wards (CW) more affected by HS and those requiring more test repetitions. We compared data from Apr-Nov 2017 (just after implementing the approach) vs Apr-Nov 2018.
Results
We detected 1447 HS (10.8%) out of 13,349 blood samples in 2017 vs 1376 HS (9.7%) out of 14,137 samples in 2018 (P=0.003), with HI2 (fHb 1-2 g/L) as the most frequent category (48% vs 39%). In the two periods, the most interfered analytes were conjugated bilirubin (CB) (37.9% vs 29.2%), ammonium (22.1% vs 13.7%), LDH (16.6% vs 15.0%), Mg (16.1% vs 11.0%) and K (12.2% vs 8.6%). We noted a significant decrease in repetition for Mg (5.0% vs 3.1%, P=0.0018) and K (3.1% vs 2.3%, P=0.0015) and a significant increase for LDH (2.4% vs 3.2%, P=0.018). CW more affected by HS were Neonatology, Pediatric and Neonatal ICUs and ER, decreasing from 31% to 27%, 29% to 17%, 22% to 19%, and 23% to 22%, respectively, in the two considered periods. Maternal ward showed hemolysis in only 0.9% of samples. CW mostly repeating tests after HS were both ICUs, ER and Pediatric Surgery. Interestingly, Neonatal ICU mainly required repetition of CB.
Conclusions
Our outline of laboratory report led to a general HS decrease. We argue that the alert comment could be a driving force able to improve the quality of phlebotomy. Beside the objective constraint of age on the possibility to repeat phlebotomy, the reduction of some test repetition and the increase of others seem to indicate an improved physicians' skill in evaluating the clinical impact of hemolysis on different tests. 
Background-aim
Reflective testing is the process of interpreting, commenting and, if necessary, adding tests by the clinical chemistry laboratory, in order to complete the diagnosis sensibly and effectively. In the Netherlands, this aspect of consultation is mainly applied to laboratory research that is requested by general practitioners. Previous research has shown that reflective testing is experienced as useful or meaningful, in 95% or more of the cases. The aim of the present study is to make an inventory of the need for reflective testing in an outpatient or hospital setting.
Methods
Questionnaires were developed for the medical specialists in gynaecology, paediatrics, cardiology and geriatrics. Each questionnaire contained of several cases -applicable to the medical specialty -in which reflective testing can be used meaningfully. In each case, respondents were asked to choose between the following options: 1) I would like to receive only the results of the requested tests; 2) I would like to receive the results with comments; 3) I would appreciate the appliance of reflective testing; 4) Otherwise. The questionnaires were distributed to medical specialists and residents of 6 general hospitals in the Netherlands.
Results
The questionnaire was completed by 87 respondents in total (gynaecology n=26, paediatrics n=32, cardiology n=16, geriatrics n=13). One third of the respondents were residents. The appliance of reflective testing was preferred in 45% of the cases; adding an interpretive comment to laboratory research was wanted in 36% of the cases. Ten percent of the respondents would only like to receive the results of the requested tests; this mainly concerned specialists in geriatrics and cardiology. The option "Otherwise" (9%) was relatively more chosen by paediatricians and gynaecologists. Further analysis of this option revealed that the specialists were generally positive about reflective testing, but that they would like to have mutual consultation about this first.
Conclusions
Medical specialists and residents reported to have a clear need for reflective testing, in case the laboratory research is indicative for this. The addition of tests and/or an interpretive comment can be seen as part of the consulting role of specialists in laboratory medicine. doi:10.1016/j.cca.2019.03.1570
